










The handle https://hdl.handle.net/1887/3176606 holds various files of this Leiden 
University dissertation. 
 
Author: Kromhout-Wegewijs, M.A. 
Title: Caffeine: a cup of care? An exploration of the relation between caffeine 
consumption and behavioral symptons in persons with dementia 











A CUP OF CARE?
An exploration of the relation  
between caffeine consumption  
and behavioral symptoms  
in persons with dementia
Michelle Kromhout

Caffeine: a cup of care?
An exploration of the relation between caffeine consumption 
and behavioral symptoms in persons with dementia.
M.A. (Michelle) Kromhout
Caffeine: a cup of care? An exploration of the relation between caffeine consumption
and behavioral symptoms in persons with dementia.
Michelle Kromhout, 2021
Department of Public Health and Primary Care of the Leiden University Medical Center
None of the studies presented in this thesis received financial support. Financial support for the 
printing of this thesis was partly provided by Tolokku.
ISBN: 978-94-6361-529-7
Cover: Design by Optima Grafische Communicatie, Rotterdam, The Netherlands. Photo by Teer-
apong Tanpanit.
Lay-out and Printing: Optima Grafische Communicatie, Rotterdam, The Netherlands
©Michelle Kromhout, 2021
This thesis is protected by international copyright law. All rights reserved. No part of this thesis 
may be reproduced, stored in a retrieval system, or transmitted - in any form or by any means – 
without the written permission from the author or, when appropriate, from the copyright-owing 
publisher.
Caffeine: a cup of care?
An exploration of the relation between caffeine consumption
and behavioral symptoms in persons with dementia.
Proefschrift
ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties




geboren 20 augustus 1983
te Helmond
Promotoren: Prof. dr. W.P. Achterberg
Prof. dr. M.E. Numans
Copromotor: Dr. N. Rius-Ottenheim
Promotiecommissie: Prof. dr. J.C. Kiefte-de Jong
Prof. dr. N.H. Chavannes
Prof. dr. S.U. Zuidema (UMCG)
Prof. dr. W.A. van Gool (Amsterdam UMC)
Prof. dr. A.M. van Hemert
To all the persons with
dementia for teaching me
what is truly important in life

Let thy food be thy medicine and medicine be thy food
– attributed to Hippocrates of Cos (c. 460 BC – c. 370 BC)
but not said nor written by him
It’s far more important to know what person the disease has
than what disease the person has 




1. Relation between caffeine and behavioral symptoms in elderly patients with 
dementia: an observational study
(Published in 2014, the Journal of Nutrition, Health & Aging, 18 407-410)
22
2. Reducing behavioral symptoms in elderly patients with dementia by regulating 
caffeine consumption: short report of two single subject trials
(Published in 2017, European Geriatric Medicine, 8 496-498)
32
3. Caffeine and behavioral symptoms in elderly patients with dementia: a systematic 
review
(Published in 2019, Experimental Gerontology, 122 85-91)
40
4. Caffeine consumption and behavioral symptoms in nursing home residents: a study 
protocol and evidence-based medicine training program
(Short version published in 2018, the Netherlands journal of Medicine, 76 138-40)
56
5. Caffeine consumption and behavioral symptoms in nursing home residents: a cross-
sectional analysis











The word “dementia” derives from the Latin stem 
‘demens’ and literally means ‘without mind.’ Demen-
tia syndrome is an umbrella term covering over 100 
diseases in which cognitive function deteriorates to 
a greater extent than seen in normal aging. Atten-
tion, planning, learning, memory, language, visual 
perception, spatial skills, social skills or other cogni-
tive functions can all be affected.(1) Alzheimer’s 
disease is the most common cause of dementia, 
accounting for 60-70% of cases, but other common 
types of dementia include vascular dementia, Lewy 
body dementia and frontotemporal dementia. At 
present, around 50 million people worldwide have 
dementia and over the next 30 years this number is 
likely to triple.(2)
Dementia affects everyone differently and has a significant physical, psychological, and social 
impact. Several factors influence the quality of life of patients with dementia.(3, 4) Factors re-
flecting relationships, social engagement and functional ability are associated with an increase 
in quality of life(4), while poorer physical health (e.g. pain), mental health (including behavioral 
symptoms)(3, 4) and poorer caregiver well-being(4) are associated with a lower quality of life. The 
global economic costs of dementia are estimated to be around $1 trillion, including the cost of 
informal care(5), so dementia has a profound effect not only on the patient but also on caregivers 
and society as a whole. Enabling people with dementia and their caregivers to “live well” and 
maintain a good quality of life should be the main focus of policy and practice (e.g. the Dutch 
‘Waardigheid en Trots’(6) and the UK’s ‘Living well with dementia’(7)).
behAvIorAL symPToms In PATIenTs wITh demenTIA
Behavior is referred to as ‘an observable response to a concrete set of circumstances’. Patients 
with dementia display non-cognitive symptoms, e.g. aggression, agitation, anxiety, apathy, which 
are together referred to as behavioral symptoms. These symptoms are also often labeled as be-
havioral problems, behavioral disturbances, challenging behavior, behavioral and psychological 
symptoms of dementia (BPSD) or neuropsychiatric symptoms.
The etiology of behavior in patients with dementia is complex and improvements to the tradi-
tional medical model regarding the presentation of dementia has been suggested by Kitwood(8):
D = NI + H + B + P + SP
A simple question
Around ten years ago, when I was working as 
a physician at a nursing home, the multidisci-
plinary team was discussing a new resident 
in the dementia special care unit. She was 
showing agitated behavior in the evening 
and at night, but had never displayed this 
kind of behavior at home. Her behavior was 
analyzed in the multidisciplinary team meet-
ing, including her (unmet) needs and pos-
sible physical or other contributing factors. 
The team then discussed treatment goals 
and options. Interestingly, the nurse men-
tioned an above average coffee consumption 
and asked whether the coffee could influ-
ence behavior. A simple question and one 
that couldn’t be answered at that time, but 
this question has stayed with me ever since.
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Kitwood proposed that the symptoms of dementia (D) can be understood as an interplay be-
tween neurological impairment (NI), psychosocial factors (health (H), individual psychology (P), 
biography (B)), and the environment (social context/psychology (SP). This proposal represented 
a rejection of the standard medical approach to dementia which focused on treating neurologi-
cal impairments (D = NI). The enhanced model resulted in the Person-centered-care philosophy, 
which is the underlying philosophy of the 2018 Alzheimer’s Association Dementia Care Practice 
Recommendations.(9) The application of this care philosophy benefits the person with dementia, 
for example in terms of improved quality of life, fewer behavioral symptoms, lower use of psycho-
tropic medication and the maintenance of self-esteem, in addition to helping staff by improving 
working conditions.(9)
Almost all patients with dementia will show behavioral symptoms at some point during the 
disease(10) which decreases quality of life of the patient with dementia(3, 4) and place a high 
burden on informal caregivers. Due to the caregiver burden, behavioral symptoms are often the 
main reason for nursing home admission in patients with dementia.(11) Behavioral symptoms are 
also associated with a decline in general health and quality of life, and increased social isolation 
of the caregiver. A higher caregiver burden often worsens the relationship between the caregiver 
and the patient with dementia, which in turn may increase the frequency and severity of neuro-
psychiatric symptoms.(12) Quick and adequate management of behavioral symptoms in patients 
with dementia is necessary to prevent further harm for the patient, caregiver overload, avoidable 
nursing home admissions and avertible society costs.
To manage behavioral symptoms, the first step recommended in guidelines is the detailed 
analysis of the patients’ behavior, including contributory physical, psychological, social and 
environmental factors, (13) after which interventions can be formulated. Many different phar-
macological treatments have been intensively studied. (14, 15) Although there is some evidence 
pharmacological agents (mainly cholinesterase inhibitors and atypical antipsychotics) can de-
crease behavioral symptoms in patients with dementia, the clinical effect is small and there are 
severe safety risks as study dropout, adverse effects and death.(14, 15) Psychosocial approaches 
have also been widely studied(16, 17) and approaches like behavioral management techniques 
or cognitive stimulation are proven reduce behavioral symptoms. But in the management of 
behavioral symptoms, no standardized solution is currently available. All interventions that target 
behavioral symptoms must be tailored to the individual(16, 18), a policy that is in line with the 
key components of person-centered care.(19) In view of these considerations, a stepped care 
approach is generally suggested as the best approach as it takes the different contribution factors 
and the individual context of the patient into account. However, even in the stepped care ap-
proach nutritional factors are not regularly included as a possible cause or intervention.
The management of behavioral symptoms in patients with dementia is complex and the burden 
for the patient and caregivers is high, often placing both caregivers and professionals at wits end. 
It is sadly no surprise that refuge is still regularly sought in pharmacological interventions, despite 
them being largely ineffective and potentially generating severe adverse effects. Therefore, fur-
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ther research into the manageable causes and eff ecti ve treatments of behavioral symptoms in 
dementi a should be one of the focal points in elderly care.
CAffeIne
Numerous anecdotes and mythological stories over the last 5,000 years(20) suggest that caff eine 
use can infl uence behavior, especially concerning a sti mulatory eff ect that can relieve fati gue and 
improve mood. In early history people chewed the leaves or seeds, such as the Mate bush or the 
cocoa bean, releasing the caff eine. The infusions with boiling water that we now know as ‘coff ee’ 
or ‘tea’ developed around 1000 AD(20), when it was discovered that boiling water enhanced 
the sti mulatory eff ect. This discovery gave rise to our current use of coff ee and tea, and drinking 
coff ee and tea today has become more than a simple consumpti on of a sti mulant, it is now a 
social event and a cultural habit. “Having a cup of coff ee” or a “tea break” are today associated 
with socializing and relaxati on.
figure 1. Chemical structure of caff eine
(adjusted from htt ps://commons.wikimedia.org/wiki/
File:Caff eine.svg)
figure 2. Coff ee, the most common form of caff eine 
ingesti on (source: Petr Kratochvil)
The ethiopian myth of coff ee
In the ancient coff ee forests of the Ethiopian plateau, the goat herder Kaldi noti ced that his goats became so 
energeti c and agitated, seemingly even dancing, that they could not sleep at night aft er eati ng the berries of a 
certain bush. The goatherd tried the berries himself and reported his discovery to the abbot of the local monas-
tery. From there knowledge of the energizing berries began to spread.
Caff eine is released when ground coff ee beans contact hot water, and the longer the contact, 
the more caff eine is released. In 1819, the German chemist Friedrich Runge isolated pure caff eine 
from coff ee, a discovery that later found applicati on in the soft  drinks industry, fi rst by adding 
caff eine as a bitt er seasoning to drinks such as Coca-Cola, Dr Pepper and Pepsi-Cola, and later by 
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adding caffeine specifically for its stimulatory effect (Xi and Red-Bull). The stimulatory effect of 
caffeine has also resulted in its use as an additive in certain medicines.
Pharmacologically, caffeine belongs to the alkaloids and is chemically related to nicotine, heroin 
and cocaine. With oral use, caffeine is absorbed by the body within about 30-60 minutes, and caffeine 
is then metabolized in the liver to three active metabolites: paraxanthine (approx. 80%), theophyl-
line, and theobromine. In healthy adults, the half-life of caffeine is around 4.5 hours on average, but 
depends on factors such as age, medication use, liver function and smoking. In elderly people with 
severe hepatic impairment, the half-life of caffeine can increase to 96 hours (see table 1).
Table 1. Pharmacokinetics and pharmacodynamic effects of caffeine
Pharmacokinetic Pharmacodynamic effects
•  Rapidly and completely absorbed from the 
gastrointestinal tract or oral mucosa
•  Non-selective antagonism of A2a and A1 adenosine 
receptors
•  tmax 15-120 min, t1/2 2-8 hours •  Facilitates dopamine D2 receptor transmission 
•  Metabolization: by CYP1A2 in the liver to paraxanthine, 
theophylline and theobromine 
•  Tolerance can develop, attributed to the upregulation of 
adenosine receptors 
•  Variability in metabolism due to age, genetics (sex, 
CYP1A2 activity), smoking, medication use 
•  Tolerance can differ between organs 
•  Excreted in the urine •  Withdrawal symptoms 12-24h after ingestion 
Caffeine is unique in that it is both water and fat soluble.(21) After ingestion caffeine can be 
found in all body fluids and can cross the blood-brain barrier, leading to a broad range of effects in 
the human body. General physical effects include but are not limited to: 1) Pain relief, 2) Increase 
in blood pressure, 3) A dose dependent effect on the heart rate (both bradycardia and tachycar-
dia), 4) Other cardiac effects including arrhythmia, 5) Vasoconstriction that increases the risk of 
myocardial ischemia, 6) Delayed conception and decreased fertility (high caffeine consumption 
increases the risk of miscarriage), and 7) Increase in bladder instability.(22)
The effects of caffeine as a stimulant partly derive from the non-selective antagonism of 
adenosine receptors, especially the adenosine A2a receptors, the A1 receptors(23, 24) and the 
adenosine A2a receptor-dopamine D2 receptor heteromer.(23) In addition, caffeine also has a 
(weaker) affinity for benzodiazepine receptor sites and several studies have shown that caffeine 
can neutralize the effects of benzodiazepines.(24) Chronic consumption of caffeine likely increases 
the number of adenosine receptors but evidence for receptor regulation of the benzodiazepine 
receptor sites is conflicting.(24) Caffeine also influences the formation and release of other 




As caffeine has been used for several centuries to influence behavior, unsurprisingly the effects 
of caffeine on behavior in adults have been widely researched. But, for many years the research 
into caffeine has been troubled by methodological challenges. In the early eighties a review(26) 
showed several weaknesses reoccurring frequently in caffeine research, namely: the use of 
weak hypothesis in experimental design, design flaws like excessive high dosages of caffeine, 
extrapolation of results from caffeine naïve to caffeine tolerant subjects and selective citation of 
literature. (Although the latter is a challenge for all research, not just caffeine research). A later 
review showed most studies still used a single high dosage of caffeine instead of the more realistic 
ingestion of several smaller dosages during the day.(27) Recently, the discussion of methodologi-
cal challenges in caffeine research focused around confounding due to withdrawal symptoms, 
the use of caffeine naive participants and the question if these participants are a representative 
sample of the population and, lastly, the influence of tolerance.(28) It is essential to take these 
specific methodological challenges in caffeine research into account while interpreting literature, 
conducting research and choosing the best intervention for a specific patient.
Despite these methodological challenges in researching caffeine, it is now widely accepted that 
moderate caffeine consumption in healthy adults increases alertness,(27, 29, 30) attention (27, 
29, 30) and cognitive function. (29, 30) It also elevates mood (30) and reduces fatigue (27). A high 
caffeine consumption (usually ≥ 300 mg) increases anxiety,(27, 30) can induce psychotic or manic 
symptoms (30) and impairs sleep (27). As these effects differ between individuals, people nor-
mally adjust their consumption of caffeine based on their personal experience of (non-)beneficial 
(side)effects.(27, 30)
In children, caffeine consumption has been linked to specific behavioral symptoms, including 
daytime sleepiness, anger and violent behavior, and an association between caffeine consump-
tion and long-term behavioral symptoms has even been suggested by some.(22)
An exploration of existing literature produced three studies(31-33) on the effect of caffeine 
on behavioral symptoms in patients with dementia (prior to this thesis). Two of these studies, 
dating from the seventies(32) and the nineties(31), used evening administration of caffeine to 
examine the effect of caffeine on sleeping difficulties. The first study wanted to investigate a pos-
sible soporific effect of caffeine in patients with dementia, of which there was anecdotal evidence 
at the time. Twelve patients with Alzheimer’s or Pick’s disease with sleeping difficulties living in 
a nursing home were included. The participants were given caffeine beverages 30-45 min before 
bedtime in 4 different dosages (0-228mg), each dosage for 5 days followed by a 1-day wash-out 
period. No soporific effect of coffee was observed.(32) The second study was a ‘reversed treat-
ment trial’. After noticing a paradoxical effect of sedatives in patients with dementia often leading 
to a reversal of circadian rhythm according to the authors, they wanted to try the opposite: a 
stimulant in de evening and a sedative in the morning. For this study 16 patients with multi-infarct 
dementia and severe sleeping difficulties with a complete reversal of circadian rhythm were given 
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caffeine at 8pm and a sedative during the day. With this treatment 10 patients showed improve-
ments in their circadian rhythm. The authors concluded that caffeine restores a normal sleep 
rhythm in patients with dementia.(31)
The third study,(33) a randomized controlled trial, examined the effect of ‘coffee therapy’ on 
behavioral symptoms measured with the Neuropsychiatric Inventory (NPI). In groups of 7-8 pa-
tients with dementia were welcomed into the room of a coffee shop by a master wearing a gown, 
an apron and a cap. Fresh coffee was grinded by the patients, after which filter coffee was made, 
sweetened and served in a china cup with saucer. Every patient was called by their name when 
receiving the coffee, and again when receiving a cracker. The coffee therapy was concluded with 
a chat, the reading of a poem or a story and was given twice a week for four weeks. The interven-
tion group showed a significant decrease in NPI. However, the authors mention they administered 
several factors together (coffee, sugar and the situation of the coffee therapy itself) to create a 
most pleasant feeling and can determine which was the most effective factor.(33)
Although the effect of caffeine on behavior in adults is widely accepted, the effect of caffeine 
on behavior in patients with dementia has not been properly investigated. As coffee is regularly 
consumed, widely available and most nursing homes do not have specific limitations or adjust-
ments in the caffeine consumption of the residents, more insight in the relation between caffeine 
and behavior in patients with dementia is wanted.
hyPoTheses
Based on the known stimulatory effects of caffeine in healthy adults, it seems logical to assume 
that, in patients with dementia, caffeine increases behavioral symptoms caused by general rest-
lessness, anger and anxiety and increases sleeping difficulties during the night by suppressing 
fatigue. In healthy adults, insufficient rest at night leads to increased sleepiness during the day, 
which may in turn lead to increased caffeine use. However, in the absence of this self-compensating 
mechanism in patients with dementia, sleeping difficulties can lead to greater daytime sleepiness 
and a reversion of circadian rhythm which in its turn can also increase behavioral symptoms (e.g. 
irritability).
The opposite can also be hypothesized: certain behavioral symptoms in patients with dementia 
can be reduced by the use of caffeine. Although the etiology of behavioral symptoms is multifac-
torial and complex,(13) factors known to induce behavioral symptoms include overstimulation 
(comparable to patients suffering from autism) and incomprehension of a situation.(34) Caffeine 
consumption may favorably impact behavioral symptoms by improving concentration and less-
ening overstimulation due to an increase in alertness. Another possible favorable mechanism 
is the social aspect of caffeine consumption. Social activities in general can reduce behavioral 
symptoms in patients with dementia, (34) and a social gathering associated with coffee drinking 
might positively influence the behavior of patients with dementia.
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To summarize, in theory caffeine consumption by patients with dementia could result in both 
an increase and a decrease in behavioral symptoms. The increase would be most likely seen 
in anxiety, general restlessness, anger and sleeping difficulties. Behavioral symptoms logical to 
decrease are those caused by overstimulation and incomprehension, which both can lead to a 
wide range of behavior. Both hypothesis were considered equally strong, therefore the aim of 
these studies was to investigate whether there is a relationship between caffeine consumption 
and behavioral symptoms in patients with dementia, and (if a relationship exists) to determine 
the direction of any effects.
desIGn
In designing the study several of the known methodological challenges in caffeine research as 
well as known difficulties in behavioral research and research in elderly care were considered:
• Several modern caffeine studies work with caffeine naïve participants or animals, which 
makes extrapolation to caffeine tolerant patients unreliable. As coffee (and caffeine) is a 
widely and regularly consumed beverage, caffeine naive patients are the minority and most 
patients have (some amount of) caffeine tolerance. Therefore, the study population should 
resemble normal caffeine consumption so reliable extrapolations could be made.
• Frail elderly persons are frequently excluded from studies due to age or comorbidity leading 
to a severe underrepresentation in scientific research. Just like in any other area of medical 
research, to advance treatment and care continuously improving and offering new insights 
are necessary. For this reason the studies have to be pragmatic, excluding as little as patients 
as possible and conducted as much as possible in normal care situations.
• Caffeine can be seen as a possible cause of behavioral symptoms or an intervention, both 
asking for different kind of designs. As caffeine is consumed regularly by elderly patients with 
dementia, it was first seen as a possible cause of behavioral symptoms. If a relation between 
behavioral symptoms and caffeine consumption is likely, then possible intervention studies 
could be done.
• Earlies studies used (extremely) high dosages of caffeine. If we want to do justice to the three 
challenges mentioned above, our conclusions should be based on normal caffeine use (no 
injections or capsules) and normal caffeine dosages (no add ons).
These considerations lead to a stepwise research design consisting of four different studies. The 
first step were two different exploratory studies to see if there was some validation in the hypoth-
eses. If these studies showed signs of a relation indicating the need for more thorough research, 




First, an observational pilot study was performed to explore the possibility of a relationship 
between caffeine and behavioral symptoms in a group of elderly patients with dementia, with a 
focus on sleep, aggression, depression, anxiety, apathy, irritability and aberrant motor behavior. 
Over four days, these behavioral symptoms were measured using the Neuropsychiatric Inven-
tory – Nursing Home edition (NPI-NH) questionnaire and a sleep questionnaire, together with 
careful observation of caffeine consumption in 29 patients with dementia (Chapter 1). Because 
caffeine shows strong individual variation in effects in healthy adults, a second exploratory study 
designed to examine the individual effects of caffeine on behavioral symptoms was performed. In 
two patients with high caffeine use and severe behavioral symptoms, caffeine consumption was 
regulated over a four-week period by serving either caffeinated or decaffeinated coffee. Behav-
ioral symptoms were then scored using the NPI-NH and the Cohan Mansfield Agitation Inventory 
(CMAI), with outcomes individualized per patient. (Chapter 2)
The results of the two exploratory studies indicated further research was warranted. Hence, a 
thorough and systematic literature review was conducted according to the Preferred Reporting 
Items for Systematic reviews and Meta-analysis (PRISMA) guidelines, with the research question 
formulated as “Does caffeine or coffee consumption influence neuropsychiatric symptoms, e.g. 
agitation, aggression, apathy, irritability, in elderly patients with dementia?”. Six (medical) journal 
databases and gray literature were searched and more than 4000 articles were screened for 
relevance, resulting in the identification of only seven relevant articles. (Chapter 3)
The final study, a large multicenter cohort study, was conducted with the aim of assessing a 
possible relationship between caffeine and behavioral symptoms in older nursing home patients 
with dementia, and if confirmed, to further assess contributory factors including the severity of 
dementia. The three-year study was embedded in the Elderly Care Physicians training program, 
and trainees collected data on caffeine consumption, cognition, behavioral symptoms (the NP-
NH, the AES-C and MDS depression) and social information. To the best of our knowledge, these 
efforts resulted in the largest existing dataset on cognition, behavior and caffeine consumption 
amongst nursing home residents (Design: chapter 4; Results: chapter 5).
Lastly, in the ‘General discussion’ the overall results of the studies will be discussed to answer 
the simple clinical question “can coffee influence behavior in patients with dementia”.
Introduction – in short
As the number of patients suffering from dementia are still growing, most of the patients experience a kind of 
behavioral symptoms at some time during the disease and these behavioral symptoms lower the quality of life 
and increase the burden of caregivers, adequate management of these symptoms is warranted. However, the 
etiology and management of behavioral symptoms is complex, resulting in (mis)use of pharmacological interven-
tions: a cure which is often worse than the disease. In adults, caffeine is known to influence behavior. Four differ-
ent studies were conducted to see if caffeine is an easy to adjust cause or a pragmatic intervention for behavioral 
symptoms in patients with dementia.
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Caffeine is known to improve concentration and reduce fatigue in healthy adults, but high doses 
may induce anxiety and agitation. Because the effects of caffeine in elderly people with dementia 
are unknown, this study explores the relation between caffeine and behavioral symptoms in a 
group of elderly patients with dementia.
Design:
An observational pilot study.
Setting:
A dementia special care unit of a Dutch nursing home.
Participants:
A total of 29 elderly patients with dementia.
Measurements:
Behavioral symptoms were measured with the NPI-NH, and sleep and caffeine consumption were 
measured using questionnaires.
Results:
A significant relation was found between the total amount of caffeine consumed during the day 
and apathy [Kendall’s tau (KT) -0.287 p=0.03], and the number of times that participants got up 
at night (KT 0.462; p <0.01). The amount of caffeine consumed after 6 p.m. was also significantly 
related to the number of times participants got up at night (KT 0.436; p <0.01). Multilevel analysis 
showed caffeine to be negatively correlated with aberrant motor behavior [b=-0.47 (0.22), Wald 
(461)=-2.12, p=0.03] and apathy [b=-0.88 (0.45), Wald (461)= -1.96, p=0.05], and showed a sig-
nificant relation between caffeine consumption after 6 p.m. and the number of times participants 
got up at night [b=0.48 (0.22), Wald (461)= 2.20, p=0.03].
Conclusion:
This study established an association between caffeine consumption and behavioral symptoms 
in elderly patients with moderately severe dementia. Therefore, adjusting caffeine consump-
tion could be part of an interdisciplinary approach to behavioral symptoms, particularly when 
aberrant motor behavior, apathy or sleeping difficulties are involved. These results indicate that 
further research on the effects of caffeine on behavioral symptoms in dementia is warranted.
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InTroduCTIon
Caffeine is a known stimulant and can interfere with several neurotransmissions including acetyl-
choline, epinephrine, norepinephrine, serotonin, dopamine and glutamate.(1) Animal and clinical 
studies suggest that caffeine can reduce cognitive decline in Alzheimer’s disease.(2, 3) Based on 
caffeine’s interference with neurotransmissions, an effect on behavior can be expected.
The effect of caffeine on the behavior of healthy adults is well studied, but with inconsistent re-
sults. One extensive review concluded that caffeine increases concentration and reduces fatigue 
in healthy adults even with normal use, but used in very large amounts or by sensitive individuals 
can also lead to increased anxiety and impaired sleep.(4) Anxiety or sleeping difficulties in people 
with dementia are referred to as behavioral and psychological symptoms of dementia, which also 
include agitation, depression, aggression, etc.
Behavioral symptoms are common in dementia. Over 80% of patients suffering from dementia 
exhibit at least one clinically relevant symptom during the course of the disease, especially agita-
tion and apathy.(5) Medication, although frequently used, has only a moderate effect in patients 
with behavioral symptoms.(6) The use of psychosocial or person-centered interventions are 
known to positively affect behavior.(7) However, the effect of caffeine on behavioral symptoms 
is unknown in elderly patients with dementia. Based on the research on the behavioral effects 
of caffeine in healthy adults, two hypotheses can be formulated on the effect of caffeine on 
behavioral symptoms in dementia: 1) caffeine might increase behavioral symptoms in dementia; 
behavioral symptoms such as agitation, aggression and sleeping problems might be a direct 
result of caffeine consumption due to its stimulating effects on the central nervous system, and 2) 
caffeine might decrease behavioral symptoms in dementia, i.e. sensory overstimulation, fatigue 
and decreased alertness can result in agitation or other behavioral symptoms in dementia. Thus, 
due to its stimulating effects, caffeine might reduce fatigue and increase alertness resulting in a 
decrease in behavioral symptoms.
Therefore, this study explores the relation between caffeine and behavioral symptoms in 
elderly patients with dementia, with a focus on sleep, aggression, depression, anxiety, apathy, 
irritability and aberrant motor behavior (AMB).
meThods
Procedure
The caffeine consumption and behavior of 29 residents living in the psychogeriatric unit of a 
nursing home were registered over a 96-h period by nursing staff, using several questionnaires. 
Baseline characteristics and the Reisberg Global Deterioration Scale (GDS) (8) were provided by 
the elderly-care physician and the medical records.
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Participants
All 31 residents living in the psychogeriatric unit were eligible for the study with the exception 
of those with active psychiatric (co)morbidity (n=0), or an expected impending death (n=1), or 
when informed proxy consent was not obtained (n=1); this left 29 available participants for the 
present study.
Consumption of caffeine
A questionnaire was used to record the number of cups of coffee, tea and cola eight times a day 
(breakfast, 10 a.m., lunch time, 2 p.m., 4 p.m., dinner time, 7 p.m. and 21 p.m.). In accordance 
with conventional practice in the Netherlands, participants were free to choose their beverages. 
The consumption of these beverages was not limited, stimulated or otherwise regulated by the 
nursing staff. During the study all coffee was drip (filter) brewed in a standardized way and served 
in a standardized cup of 150 ml, with a caffeine content of approximately 85 mg per cup.(9)
behavioral problems
Behavioral symptoms were scored using an adaptation of the Neuro Psychiatric Inventory-Nursing 
Home edition (NPI-NH).(10, 11) The NPI-NH is a reliable and valid observation scale which registers 
the presence, severity and frequency of behavioral symptoms, and the burden for caregivers.(12) 
Because the present study focused on specific types of behavior the items addressing delusions, 
hallucinations, euphoria, disinhibition and appetite were excluded, and only the items agitation/
aggression, depression/dysphoria, anxiety, apathy/indifference, irritability/lability and AMB were 
scored at the end of every 8-h nursing shift, by the on-duty nurse.
Sleep problems were defined as night-time behaviors such as wandering around, but also as 
the inability to sleep, i.e. lying awake in bed. Instead of the NPI item ‘nighttime behaviors’ we 
used a specially developed night-time questionnaire which recorded whether a participant got 
up at night (including frequency and reason) and whether the participant lay awake in bed or 
was asleep. The participants were closely observed during 4 consecutive nights. All nursing and 
nutrition staff were trained in the use of the questionnaires administered in this study.
statistical analysis
Initially, associations between the total caffeine consumption (during 96 h) and the presence/
absence of a specific behavioral symptom (during 96 h) were calculated (SPSS 15.0) using non-
parametric Kendall’s tau correlation coefficient (KT), due to the small sample size, longitudinal 
dependency and not normally distributed data.
Because of the nested structure of the data, with (repeated) observations nested within in-
dividuals, the data were also analyzed using multilevel analysis. In this analysis data was were 
perceived as made up of two levels. The first level consisted of the repeated measurements of 
caffeine consumption (the independent variable), AMB, aggression, depression, anxiety, apathy 
and irritability (dependent variables). On this level each individual´s scores on a dependent 
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variable were related to their scores on the independent variable using linear regression equa-
tions. The second level consisted of the individuals participating in the study. On this level inter-
individual differences in the model parameters of the first level (i.e., the regression coefficients) 
were modeled. In the current study no predictors for inter-individual differences were included; 
this means that the parameter values were modeled as normally distributed across individuals. 
For every dependent variable a separate multilevel analysis was done, and for every dependent 
variable two models were constructed. The first model analyzed the relation between caffeine 
and behavioral symptoms during the same time frame, i.e. caffeine consumed in the morning and 
any behavioral symptoms observed during the morning. However, because the effect of caffeine 
can last several hours, the relation between caffeine consumption and behavioral symptoms in 
the subsequent time frame was analyzed in the second model. All variables were entered into 
the multilevel analysis. Effects that were not significant in this analysis were step-wise removed 
to arrive at the final models.
resuLTs
Participants
The participants had a mean age of 84 (SD 6.6) years and suffered from moderate to severe 
dementia (Table 1). Over 50% was diagnosed with Alzheimer’s disease. Although 12 of the par-
ticipants used psychotropic drugs on the study days, none of the dosages was adjusted in the 4 
weeks prior to or during the study.
Coffee consumption
During 96 h the participants consumed on average 15 (SD 5.6) units of caffeine. On the first morn-
ing the participants consumed a mean of 1.4 (SD 0.9) units of caffeine, followed by 1.8 (0.9), 1.6 
(1.5) and 1.4 (1.0) units of caffeine on the subsequent mornings. In the evenings an average of 1.8 
(0.8), 1.1 (0.7), 0.8 (0.5) and 1.6 (0.9) units of caffeine were consumed, respectively.
behavioral problems
Of the 29 participants, 6 showed no behavioral problems of any kind during the entire observation 
period. The majority (n=18) showed a behavioral symptom to a maximum of once a day, whereas 
5 had behavioral symptoms at least once a day. Irritability was the most frequent (n=20), followed 
by AMB (n=12). Aggression was observed in 9 participants, 5 of whom displayed aggression more 
than once during the observation period.
There was a significant negative correlation between the total amount of caffeine consumed 
and apathy (KT -0.287; p=0.03). Other forms of behavioral symptoms had no significant correla-
tion with daily caffeine consumption (Table 2).
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In the first multilevel analysis, the relation between caffeine consumption and behavior was 
analyzed in the same time frame. A significant negative correlation was found between total daily 
caffeine consumption and AMB [b=-0.47(0.22), Wald (461)= -2.12, p=0.03] and apathy [b=-0.88 
(0.45), Wald (461)= -1.96, p=0.05].




Age in years: mean (range) 84 (69-96)
Dementia (n)
Alzheimer’s disease 16
Vascular dementia (VD) 4
Alzheimer’ disease/VD 1
Korsakoff’s syndrome 1
Not otherwise specified 7
Reisberg Global Deterioration Scale (n)
5 = Moderate 8
6 = Moderately severe 14
7 = Severe 7
Renal function: mean ml/min (range) 59 (26-90)









Table 2: Relation between behavior and total caffeine consumption per day (Kendall’s tau correlation coef-
ficient).






Aberrant motor behavior 0.850 p=0.29
Sleep: waking up at night 0.043 p=0.38
Sleep: getting up at night 0.462 p<0.01*
* statistically significant
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The second multilevel analysis showed no significant correlation between apathy, AMB, ag-
gression, depression, anxiety or irritability and caffeine consumed in the previous time frame. 
(Table 3).
Quality and quantity of sleep
The nurses walked three rounds each of the 4 nights, totaling 12 observations per participant 
with a total of 348 observations. Only 3 participants slept continuously during all 4 nights. Of the 
remaining participants, 3 slept during the nurses’ rounds but got up between the rounds, and 23 
often lay awake in bed and/or walked around. Of the study participants, 14 (48%) did not get up 
during the night; the remaining 15 were seen a total of 108 times out of bed by the nurses during 
the observation period. The most common reason for getting out of bed was to use the bathroom 
(97 of 108) and, occasionally, just to stretch the legs (3 of 108) and/or due to a general feeling of 
restlessness (8 of 108). No behavioral symptoms, such as aggression or agitation, were observed 
during the night.
There was a significant correlation between caffeine consumption during the day and the num-
ber of times that participants got up at night (KT 0.462; p <0.01) (Table 2). The amount of caffeine 
consumed in the evening was also significantly correlated with the number of times participants 
got up at night (KT 0.436; p <0.01).
In the multilevel analysis, the total amount of caffeine consumed each day showed no signifi-
cant relation with any form of sleeping problems. However, the amount of caffeine consumed in 
the evening (after 6 p.m.) was significantly related to the number of times that participants got 
out of bed [b=0.48 (0.22), Wald (461)= 2.20, p=0.03] (Table 3).
dIsCussIon
In this sample of elderly patients with dementia living in a special care unit a negative correla-
tion between caffeine consumption and apathy and AMB was found. Caffeine consumption after 





Apathy b=-0.88 (0.45), Wald (461)= -1.96, p=0.05* b=-0.49 (0.69), Wald (432)= -0.72, p=0.47
Depression b=-0.31 (0.29), Wald (461)= 1.01, p=0.28 b=0.34 (0.36), Wald (432)= 0.94, p=0.35
Anxiety b=0.48 (0.48), Wald (461)= 1.00, p=0.32 b=1.53 (0.91), Wald (432)= 1.68, p=0.09
Aggression b=0.22 (0.27), Wald (461)= 0.84, p=0.40 b=-0.15 (0.24), Wald (432)= -0.60, p=0.55
Irritability b=-0.22 (0.15), Wald (461)= -1.40, p=0.16 b=0.19 (0.18), Wald (432)= 1.07, p=0.29
Aberrant motor behavior b=-0.47 (0.22), Wald (461)= -2.12, p=0.03* b=0.49 (0.32), Wald (432)= 1.54, p=0.12
* statistically significant
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6 p.m. was correlated with getting out of bed at night. No significant correlations were found 
between caffeine and aggression, depression, irritability or anxiety.
This pragmatic, observational study is the first study to explore the effects of caffeine on sleep 
and behavior in patients with dementia but has some limitations which need to be discussed. 
First, caffeine was ingested orally and consumption was recorded, but serum caffeine levels were 
not measured. Also, individual differences in caffeine metabolism are likely and could have influ-
enced the results. Second, the observational period was short (96 h). However, because the effect 
of caffeine usually lasts only a few hours it is likely that any effect of caffeine on behavior would 
be observed during the 96-h observation period. Third, the sample size was small. Despite these 
limitations, correlations were found between caffeine consumption and behavioral symptoms, 
representing a medium to large effect size which can, therefore, be considered relevant.
In the present study, caffeine consumption was negatively correlated with AMB and apathy. 
AMB encompasses a wide range of repetitive, often purposeless behaviors like wandering, pac-
ing or plucking and is frequently used interchangeably with agitation.(13) Apathy is almost the 
opposite, a loss of motivation leading to diminished activity and attention. Apathy is a frequently 
occurring neuropsychiatric symptom of dementia, with a reported prevalence of around 30%.(5) 
The negative correlation between apathy and caffeine might be a result of apathy itself, with the 
participants being too apathetic to consume coffee, but might also imply that caffeine consump-
tion can be used as a therapeutic measure. A possible mechanism for this inverse correlation 
between caffeine and both apathy and AMB is through the acetylcholinesterase pathway. The 
acetylcholinesterase inhibitor rivastigmine is known to reduce both apathy and AMB in nursing 
home residents with moderate to severe Alzheimer’s disease.(14) Caffeine is also a non-compet-
itive inhibitor of acetylcholinesterase.(1) Using caffeine as a therapeutic measure in both apathy 
and AMB might, therefore, be an interesting therapeutic option.
Changes in sleep behavior are common in dementia(15) and sleep disorders tend to be more 
severe in patients with dementia compared to those found in the elderly without dementia.(16, 
17) Sleeping abnormalities are associated with an increase in cognitive decline, caregiver burden 
and behavioral symptoms in patients with dementia.(16) Therefore, it is important to identify and 
adequately treat all factors contributing to sleeping difficulties. In the present study, no relation 
between caffeine use and lying awake in bed was found, which is consistent with a previous 
study.(18) However, caffeine use after 6 p.m. was significantly correlated with the number of 
times participants got out of bed at night, mostly to use the bathroom. The sleeping difficulties 
observed in this study cannot be explained by the stimulating effects of caffeine (increased alert-
ness and decrease fatigue), but could simply be due to the diuretic effects of caffeine. Therefore, 
reducing caffeine consumption after 6 p.m. in patients who get out of bed frequently during the 
night, especially combined with frequent noctural micturation, could be a simple intervention to 
improve sleep in elderly patients with dementia.
In conclusion, in these residents, caffeine consumption is negatively correlated with apathy and 
AMB and positively correlated with getting out of bed at night. Regulation of caffeine consump-
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tion might be an easy, inexpensive and effective way to influence behavioral symptoms in elderly 
with dementia, especially when AMB, apathy or sleeping difficulties are involved; further study 
seems to be warranted.
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Caffeine is a stimulant with strong individualized effects in adults. In elderly patients with demen-
tia there is a group relation between caffeine and apathy, aberrant motor behavior and sleeping 
difficulties. A single-subject trial was designed to examine the individual effects of caffeine on 
behavioral symptoms in older adults with dementia.
Method
Two blinded crossover single-subject trials were conducted in a dementia special care unit. 
During a 4-week period, caffeine consumption was partly regulated by using caffeinated (C) and 
decaffeinated (D) coffee pads, in a predetermined order (C-D-D-C). Behavioral symptoms were 
measured with the NPI-NH and CMAI, and caffeine consumption was measured using question-
naires.
Results
In participant A the specific behavioral symptoms decreased in the ‘decaf weeks’ and increased 
slightly when caffeinated coffee was reintroduced (NPI-NH item agitation/aggression scores on 
weeks 1-4: 12, 3, 1 and 4, respectively). The same pattern emerged in the total CMAI score, the 
CMAI physically aggressive cluster scores, the CMAI non-aggressive behavior cluster scores, the 
total NPI-NH score and the NPI-NH psychomotor behavior cluster score. In contrast, in participant 
B no relation was found between caffeine consumption and behavioral symptoms.
Conclusion
Behavioral symptoms in elderly patients with dementia are complex and require detailed analysis. 
In some patients, behavioral symptoms can be reduced by a relatively simple regulation of caf-
feine consumption. A personalized treatment approach is necessary, especially if relatively simple 
interventions can improve the burden for patients and caregivers.
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InTroduCTIon
Behavioral and psychological symptoms are common in older patients with dementia and place a 
considerable burden on formal and informal caregivers.(1, 2) The etiology of behavioral symptoms 
is complex and probably multifactorial. Although many interventions have been well investigated, 
tailoring these results for the individual patient remains a challenge. Therefore, an individualized 
approach is necessary.(3)
Caffeine is a commonly consumed stimulant and normal use is known to increase alertness and 
reduce fatigue. (4) If used in high amounts, caffeine can increase or induce anxiety, restlessness, 
insomnia and psychomotor agitation.(4, 5) However, the stimulating effects of caffeine show a 
large individual variation and most people tend to control the caffeine consumption themselves 
to avoid adverse effects. (4, 5)
The effect of caffeine on behavioral symptoms in older patients with dementia is not exten-
sively investigated. A small pilot study in older patients with dementia showed that caffeine 
consumption was associated with apathy, aberrant motor behavior and sleeping difficulties.(6) 
However, individual variation in the effects of caffeine on behavior impedes translating these 
results to clinical practice. Therefore, to further examine and quantify the individual effects of 
caffeine on behavioral symptoms, two single-subject trials were performed with two older adults 
with dementia.
meThods
In elderly care, a randomized trial presents substantial methodological barriers, e.g. likely loss 
to follow-up and the risk of bias by multimorbidity. (7) The single-subject trial is also a random-
ized blinded study, but conducted with one single patient. It is seen as the ultimate proof for 
the individual patient,(8) especially if the intervention has shown variation in efficacy between 
patients,(7) as is the case when considering the effects of caffeine.
In an earlier study , the caffeine consumption and behavior of 29 residents of a dementia spe-
cial care unit was registered.(6) Of these residents, eligibility for the present single-subject trial 
included both a high intake of caffeine and severe behavioral symptoms. Four residents met these 
criteria. Those with active psychiatric (co-)morbidity(n=1) and those in whom informed proxy 
consent was not achievable(n=1) were excluded. This left two residents. As both were legally 
incapable to give consent, informed proxy consent was obtained. The local ethics committee was 
also informed. Withdrawal was possible at any time at the request of the legal representative or 
staff as they saw fit, without any consequences.
The caffeine consumption was regulated during a 4-week period by serving caffeinated (C) or 
decaffeinated (D) coffee in a predetermined order per week (i.e. C-D-D-C) to allow for a washout 
period. The residents and staff were unaware of the predetermined order, and also blinded for 
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the intervention using unrecognizable coffee pods in unmarked tins. A questionnaire was used to 
record the number of cups of coffee and of tea consumed during the day. The consumption of 
these beverages was neither limited nor stimulated by the staff.
Behavioral symptoms were scored using the Neuro Psychiatric Inventory-Nursing Home edi-
tion (NPI-NH) (9, 10) and the Cohen Mansfield Agitation Inventory (CMAI).(11, 12) The NPI-NH 
assesses 12 neuropsychiatric symptoms. The frequency and severity are rated and are multiplied 
to create a symptom score (range 1-12). The total score is the sum of all 12 symptoms (range 12-
144). The NPI identifies three clusters of symptoms: psychosis, psychomotor behavior, and affect.
(13) The CMAI assesses 29 agitated behaviors in patients with dementia. All items are scored on a 
7-point scale (range 29-203). The CMAI focuses on three clusters of symptoms: physically aggres-
sive, physically nonaggressive and verbally agitated behavior.(14) Both rating scales are validated 
for use in Dutch nursing homes (14) and, in the present study, were scored weekly by a nurse.
resuLTs
Participant A
The first participant is an 85-year-old woman, diagnosed with Alzheimer’s disease. In the nursing 
home she continuously paces through the unit. There is a general restlessness and, occasionally, 
sadness but no other signs of depression are apparent. If she does not feel in control, she becomes 
angry and hits the nurses or residents. A detailed multidisciplinary analysis was conducted follow-
ing national guidelines. (15) As no physical cause was found, environmental and psychological 
interventions were set in place. Additionally, in the presence of physical aggression endangering 
herself or others, a small dose of lorazepam was given. A single-subject trial was initiated to 
examine whether this patient’s high level of caffeine consumption influenced her general restless-
ness, agitation and aggression.
During the 4-week observation period, 3212 mg of caffeine was consumed: 67% from coffee. 
During the ‘decaf weeks’ (weeks 2 and 3), 19% of the total amount of caffeine was consumed. 
There was no medication or comorbidity present which could interfere with caffeine metabolism. 
The reduction in caffeine consumption coincided with a reduction of NPI-NH item agitation/ag-
gression (scores for weeks 1 to 4 were: 12, 3, 1 and 4, respectively) (Table 1). After the reintroduc-
tion of caffeine, there was a slight increase in these behavioral symptoms. The same pattern was 
seen in the total CMAI score, the CMAI item general restlessness, the CMAI physically aggressive 
and non-aggressive cluster scores, the total NPI-NH score and the NPI-NH psychomotor behavior 
cluster score. The decrease of the total NPI-NH score was almost entirely attributable to the items 
agitation/aggression, irritability and aberrant motor behavior. The changes seen in the total CMAI 
score were due to several items, including general restlessness and aggressive behavior (Table 1).
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Table 1: Results of the trial: participant A
week 1 (C) a week 2 (d) a week 3 (d) a week 4 (C) a
Caffeine (total mg)b 1420 303 309 1180
CMAI (total) 60 51 44 51
CMAI item scoresc
Pacing 6 6 5 6
Inappropriate robing/disrobing 5 5 5 5
Cursing or verbal aggression 5 3 1 3
Hitting 4 2 1 1
Grabbing 4 2 1 1
Pushing 1 1 1 2
Get to different place 3 1 4 1
Hoarding things 6 5 5 6
General restlessness 6 6 1 6
CMAI cluster scores
Physically aggressive behavior 18 12 8 11
Physically non-aggressive behavior 28 25 22 26
Verbally agitated behavior 4 4 4 4
NPI-NH (total) 49 25 1 8
NPI-NH item scoresd
Agitation/aggression 12 3 1 4
Depressed mood 9 0 0 0
Irritability 12 8 0 0
Aberrant motor behavior 12 12 0 4
Might time behavior 4 2 0 0
NPI-NH cluster scores
Psychosis 0 0 0 0
Psychomotor behavior 24 11 1 4
Affect 9 0 0 0
a C: caffeinated coffee; D: decaffeinated coffee
b cup of tea 30 mg; cup of coffee 70 mg; cup of decaffeinated coffee 3 mg
c all other CMAI items (spitting, constant request for attention, repetitious sentences/ questions, kicking, throw-
ing things, making strange noises, screaming, biting, scratching, intentional falling, complaining, negativism, eating 
inappropriate substances, hurting oneself or others, handling things inappropriately, hiding things, tearing things, 
performing repetitious mannerisms, verbal sexual advances and physical sexual advances) had a continuous score 
of 1 during the study
d all other NPI-NH items (delusions, hallucinations, anxiety, euphoria, apathy, disinhibition and eating change) had a 
continuous score of 0 during the study
CMAI: Cohen Mansfield Agitation Inventory
NPI-NH: Neuro Psychiatric Inventory-Nursing Home edition
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Participant b
Participant B, a 91-year-old woman, was diagnosed 6 years earlier with mixed type dementia. 
After admission, she kept to herself. If someone entered her room she became angry and ag-
gressive, often pushing people out of the room. Her family perceived her behavior as being ‘her 
nature’. Following the national guidelines,(15) an extensive multidisciplinary evaluation of her 
behavior was made, resulting in environmental and psychological interventions. No psychotropic 
medication was prescribed. A single-subject trial was initiated to investigate whether her high 
level of caffeine consumption influenced her anger and aggression. However, during the 4-week 
observation period no relationship was found between total caffeine consumption.
dIsCussIon
Two single-subject trials were performed to explore whether specific behavioral symptoms could 
be reduced by regulating caffeine consumption in older patients with dementia with high caffeine 
intake and behavioral symptoms.
In participant A, the behavioral symptoms decreased in the ‘decaf weeks’ and increased slightly 
when regular coffee was reintroduced. In participant B, no relationship was found between caf-
feine consumption and behavioral symptoms.
This is the first report of single-subject trials to investigate the effects of caffeine on the man-
agement of behavioral symptoms in older patients with dementia. To evaluate the clinical value 
of the results, the limitations and strengths of the study need to be addressed. In these trials, 
the CMAI ratings pertain only to the week prior to the administration of the CMAI, instead of 
the usual 2-week period. However, because of the frequent nature of the behavioral symptoms, 
it is unlikely that our results were adversely affected. On the other hand, this study has several 
strengths. First, both the NPI-NH and the CMAI were scored by a single caregiver who knew the 
participant well; this is known to increase the validity of the ratings.(13) Second, although this 
was a real-life situation, no other interventions took place during the trial period (e.g. pharmaco-
therapy), which serves to increase the internal validity.
In general, the single-subject trial is uniquely suited for individualized research: it is a fast and 
flexible method to evaluate treatment effects, especially in complex situations. Moreover, the 
double-blinded crossover design creates a perfectly matched control. However, it is less suited 
for generalization to all patients with dementia and behavioral symptoms. This makes the single-
subject trial the ideal design to determine individual effects of caffeine on specific behavioral 
symptoms.
Caffeine can have a positive or negative effect, depending on the amount consumed and the 
individual sensitivity. The single-subject trials presented here reveal the differences between the 
individuals.
Chapter 2 | Two single-subject trials
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Several reviews have shown that individuals generally regulate their caffeine consumption 
to maximize the beneficial effects and decrease negative effects.(4, 5) However, patients who 
are dependent on others, such as patients with dementia, are unable to regulate this and are, 
therefore, more likely to experience negative effects.
In conclusion, behavioral symptoms seem to be influenced by caffeine consumption in some 
older patients with dementia. In accordance with the effects of caffeine in adults, there seems to 
be a strong individual effect and tolerance to caffeine in older patients. These two single-subject 
trials support the need for detailed analysis of behavioral symptoms in dementia and also show 
the need for individually-based management of behavioral symptoms.
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The consumption of caffeine has well known effects on the behavior and sleep of healthy adults. 
Behavioral symptoms and sleeping difficulties are common in patients with dementia which may 
be affected by caffeine consumption. This systematic review examines the association between 
caffeine intake and neuropsychiatric symptoms in patients with dementia.
Methods:
In January 2019 an extensive search was conducted in Medline (PubMed), Embase, Emcare, 
Cochrane, PsychInfo, Web of Science and gray literature. Studies were included when they: i) 
investigated patients diagnosed with dementia, ii) reported neuropsychiatric symptoms, iii) used 
caffeine or coffee consumption as an intervention, and iv) reported associations between caffeine 
or coffee consumption and neuropsychiatric symptoms. Studies were excluded when they also 
included participants without a diagnosis of dementia, or presented a review or expert opinion. 
Two reviewers independently rated the studies and reached consensus on the appraisal.
Results:
Of the seven studies eligible for this review, four reported on sleeping difficulties and five on be-
havioral symptoms. There was no consistent effect of caffeine administration on neuropsychiatric 
symptoms: e.g., both high caffeine consumption and eliminating caffeine were associated with 
less apathy, the total Neuropsychiatric Inventory (Nursing Home) decreased after both coffee 
therapy and after eliminating caffeine, and both caffeine consumption and eliminating caffeine 
improved sleep.
Conclusion:
These findings suggest that caffeine can either induce or reduce neuropsychiatric symptoms in 
individual patients with dementia. Therefore, in these patients, caffeine consumption requires 
a prudent individualized approach and further research on the effects of caffeine on individual 
neuropsychiatric symptoms in required.
Chapter 3 | A systematic review
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InTroduCTIon
In 2018 around 50 million people worldwide were reported to have dementia, with consider-
able impact on the patients and their caregivers.(1) Neuropsychiatric symptoms (e.g. aggression, 
agitation, anxiety, depression) are common in patients with dementia(2, 3) and lower the quality 
of life of both patients (4) and their caregivers.(5) Moreover, the etiology of these symptoms is 
complex and thought to be multifactorial, requiring detailed analysis of the contributory factors, 
followed by stepwise, tailored interventions.
In some guidelines on problematic behavior in dementia, caffeine is mentioned as a possible 
contributing factor in agitated behavior during the night (6) and, in healthy adults, is known to 
have physical effects on the body (e.g. increased diuresis) and influence behavior. For example, 
normal caffeine consumption in healthy adults increases alertness,(7-10) attention(7, 8, 10) and 
cognitive function,(7, 8) and elevates mood(8, 11) and reduces fatigue.(10) In higher dosages 
(usually ≥ 300 mg) caffeine may increase anxiety,(8, 10, 12) and induce psychotic or manic symp-
toms.(8) Caffeine intake prolongs sleep latency,(10, 12, 13) reduces sleep duration,(10, 12, 13) 
sleep efficiency(13) and fatigue(8), and also reduces subjective quality of sleep.(13) In adults, the 
effects of caffeine on sleep are dose and time dependent.(10, 13) The effect of caffeine on sleep 
and behavior in older persons is less well investigated. However, both older people and individu-
als with mental health problems may be more sensitive to caffeine compared to younger adults.
(13) This places older people with dementia at potentially higher risk for an adverse influence of 
caffeine on behavior and sleep.
In view of the clear effects of caffeine on behavior and sleep in adults and the prevalence of 
neuropsychiatric symptoms in older patients with dementia, we hypothesized that there would 
be a correlation between caffeine intake and neuropsychiatric symptoms in patients with de-
mentia. Therefore, this review examines the association between caffeine and neuropsychiatric 
symptoms in older patients with dementia.
meThods
search strategy
This systematic review was designed according to the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines.(14, 15) Details of the protocol were registered 
at PROSPERO and can be assessed at http://www.crd.york.ac.uk/PROSPERO/display_record.
php?ID=CRD42018094098.
In January 2019 the following databases were searched: Medline (PubMed), Embase, Emcare, 
Cochrane, PsychInfo and Web of Science. At the same time, a second search was conducted 
in the gray literature: GLIN, Greylit, AACN Research & Data center, WHO, OpenGray, HSO and 
Clinicaltrials.gov. Moreover, all references of eligible articles were scrutinized for potential ad-
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ditional studies. The search strategy was designed by the authors in collaboration with a medical 
information specialist.
selection
Two reviewers (MK and NRO) independently conducted the search and assessed the relevance of 
each article. The reviewers compared the articles and reached consensus on the final eligibility of 
each article. Another independent reviewer was available if consensus was not reached; however, 
involvement of a third reviewer was not required.
Studies were included when they: i) included patients diagnosed with dementia, ii) reported 
neuropsychiatric symptoms, preferably using a valid scale or index: e.g. the Neuropsychiatric 
Inventory (NPI) (16) or the Cohen-Mansfield Agitation Inventory (17), iii) included caffeine or 
coffee consumption as an intervention, and iv) reported associations between caffeine or coffee 
consumption and neuropsychiatric symptoms.
Studies were excluded when they also included participants without a diagnosis of dementia, 
or presented a review or expert opinion.
data extraction
One reviewer (MK) extracted the following data: study characteristics (authors, year of publica-
tion, country, study design, inclusion/exclusion criteria), patient characteristics (number, mean 
age, sex, type of dementia), caffeine, neuropsychiatric symptoms (scale/index used, results), 
associations between caffeine and neuropsychiatric symptoms, adjustments made for confound-
ing/risk of bias, and funding. The data extraction was checked by a second reviewer (NRO).
Appraisal
Since this review included mixed method studies, the Mixed Methods Appraisal Tool (MMAT) 
was used during the appraisal stage. The MMAT has been designed to assess the methodologi-
cal quality of studies included in a systematic mixed studies review. The MMAT consists of two 
screening questions and five sections of specific questions regarding study type, e.g. qualitative, 
quantitative randomized controlled trial (RCT), quantitative non-RCT, quantitative descriptive, and 
mixed methods. For a mixed methods study three sections were used, i.e. the qualitative section 
to appraise the qualitative component, the appropriate section for the quantitative component, 
and the mixed methods section. For all types of studies, an overall quality score was calculated 
to indicate methodological quality.(18) Two reviewers (MK and NRO) independently assessed 
the studies and reached consensus on the scoring metrics. However, since one of the reviewers 
(MK) co-authored two of the included studies, in the assessment of these latter studies MK was 
replaced by the third reviewer (EJG).




The primary search resulted in 3,239 potentially relevant articles; after screening for eligibility, 
only 7 studies remained. The secondary search yielded 788 potentially relevant articles, of which 
none met the inclusion criteria (Fig. 1).
figure 1: flowchart
study characteristics
The seven included studies differed in almost all aspects, including: i) study type (from a case 
report(19) to a RCT(20)), ii) publication date (ranging from 1976 (21) to 2018 (22)), and iii) meth-
odology (qualitative and quantitative). However, all studies included patients with some type of 
dementia.
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One study excluded patients with certain types of dementia.(21) In five studies caffeine was 
regulated,(20-24) one study observed caffeine consumption(25) and one used self-reported 
consumption.(19) Three studies measured behavioral problems,(19, 20, 24) two studies reported 
on sleeping difficulties(21, 23) and two studies reported on both.(22, 25) Characteristics of the 
included studies are presented in Tables 1 and 2.
Appraisal
The one quantitative RCT, and the one mixed method and five quantitative non-RCTs were 
scored using the MMAT criteria. The mixed method study(21) scored lowest (0%), mainly due 
to the qualitative part of the study in which none of the MMAT criteria were met. The oldest 
quantitative non-RCT(23) lost points (MMAT score 25%) due to unclear selection, inappropriate 
measurements, and the absence of control persons. Three studies scored 50% on the MMAT.(19, 
22, 24) The qualitative case report did not analyze the data and did not consider the influence of 
the researchers.(19) In the two single-subject trials (both reported in (24)), the participants were 
carefully selected and the article did not report complete outcome data. The most recent qualita-
tive non-RCT also had incomplete outcome data and did not correct for possible confounders.
(22) The other two studies met all the criteria for the appropriate study method.(20, 25) (Tables 
1 and 2)
Caffeine or coffee consumption
In all studies, the investigated hypothesis was whether caffeine was a determinant for the 
reported neuropsychiatric symptoms. However, the way the caffeine was ingested ranged from 
injections,(23) caffeinated beverages,(20-22, 24, 25) medication,(19) to oral ingestion (not further 
specified).(23) The following were used as (de)caffeinated beverages: instant coffee, filter coffee, 
pour-over coffee, coffee from pads, black tea and cola.
The amount of caffeine in coffee varies according to the method used to make the coffee, e.g. 
filter coffee contains more caffeine than espresso due to the longer extraction time. Two studies 
mentioned the exact caffeine dosage,(21, 23) two made estimates based on the method of coffee 
making,(24, 25) and one study made an estimation based on self-reported medication use.(19) 
Since two trials did not mention caffeine dosage during the intervention (20, 22), an estimation 
was made (if possible) based on the information in the article. In the seven studies, caffeine 
consumption ranged from 0-300 mg/day, and was reported to be 1300 mg/day in the case report 
(Table 3).
neuropsychiatric symptoms
Two trials,(20, 22) the two single-subject trials,(24) an observational study,(25) and the case 
report(19) assessed the relationship between caffeine and various behavioral symptoms. The 
included studies reported both positive and negative effects of caffeine on behavioral symptoms.
Chapter 3 | A systematic review
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Table 1: Characteristics of the studies with sleep as outcome
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CMAI: Cohen-Mansfield Agitation Inventory; AMB: aberrant motor behavior; F: female; VD: vascular dementia; FTD: 
frontotemporal dementia; NOS: dementia not otherwise specified
1 Authors do not explicitly state the country of study, but both are affiliated with the University of Rochester, New 
York, USA. 
2 All non-significant results are also reported in the article.
3 More results reported in the article. None of the articles mention funding.
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Table 2: Characteristics of studies with behavior as outcome.
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2 More results reported in the article.
None of the articles mention funding.
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The trial from Japan used the NPI to measure the difference in neuropsychiatric symptoms be-
tween coffee therapy and control therapy in a group of 29 patients with dementia.(20) Coffee 
therapy was described as a 30-min social activity in which fresh coffee was ground, brewed and 
served. Compared to the control group, the coffee therapy group had a significant drop in the to-
tal NPI score.(20) In one of the single-subject trials, a decrease in total Neuropsychiatric Inventory 
Nursing Home edition (NPI-NH) was seen during the decaffeinated period.(24) The other studies 
did not report the total NPI-NH score, but reported on specific NPI-NH items. In the observational 
study, a higher use of caffeine was associated with a lower score on the NPI-NH item ‘apathy’ and 
a higher score on ‘aberrant motor behavior’.(25) Interestingly, the most recent study showed a 
decrease in ‘apathy’ after eliminating caffeine after 12 a.m. and no relation with ‘aberrant motor 
behavior’.(22) One of the single-subject trials showed no effect of caffeine on behavior, whereas 
the other showed a negative effect of caffeine on several NPI-NH items (e.g. agitation/aggression) 
and on the NPI-NH psychomotor behavior cluster score.(24) The case report identified caffeine 
abuse, in combination with aspirin, as being the main cause of psychoses.(19)
Four studies reported on sleeping difficulties (Table 2). Caffeine was found to increase the 
number of times patients with dementia got out of bed (25) and eliminating caffeine increased 
the number of times patients with dementia were quietly sleeping and also improved the total 
sleep score,(22); these effects are similar to those reported in healthy adults. However, in contrast 
to the effects in healthy adults, in patients with dementia no relationship was found with sleep 
induction time,(21) quality of sleep,(21) time awake during the night(21, 25) and global sleep 
rating.(21) In two trials caffeine was administered in the evening, i.e. at 8 p.m. (23) or 30-45 min 
before bedtime(21). In both these studies some of the participants showed an improvement in 
sleep: 3 of 12 showed increased sleep on 138 mg of caffeine and 10 of 16 showed improvement 
in the circadian rhythm.
Table 3: Caffeine consumption and results per study
study (estimated) caffeine consumption (per day) result
Ginsburg 0mg – 48mg – 138mg – 228mg In 3 patients increased sleep on 138mg
Domzal 0,1 – 0,2 caffeine (oral or per injection) 10 patients improved their duration of sleep
Matsuda ½ cup filter coffee 2/week
Estimate: 85mg/2/7*2 = 12mg
NPI score on baseline 23, at the end 15
Kromhout 2014 Average use 15 units of caffeine pp in 4 
days: 85mg*15/4 = 319mg
Negative correlation with apathy and AMB
Positive correlation with getting up at night
Golden 5-20 packets a 65mg = 325 – 1300mg Psychoses
Kromhout 2017 203mg – 43mg – 44mg – 169mg Relation between specific NPS and caffeine 
consumption
Pooter Baseline: mean 300mg (range 150-375)
Intervention: no caffeine after 12 a.m.
Eliminating caffeine in the afternoon and evening 
decreases apathy and improves sleep.
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dIsCussIon
Although caffeine is widely used and its effects have been extensively studied in healthy adults, 
our comprehensive search yielded only seven small studies assessing the relation between caf-
feine consumption and neuropsychiatric symptoms in patients with dementia. Thus, the evidence 
is limited and most studies had methodological issues. Despite our thorough analysis of these 
studies, no consistent conclusions could be drawn regarding caffeine consumption and neuro-
psychiatric symptoms in patients with dementia. However, in each trial, the behavior of some 
participants seemed to be (strongly) influenced by caffeine consumption but in unpredictable 
ways, thereby emphasizing the need for an individualized approach.
The absence of a consistent effect might be due to the relatively normal dosage of caffeine used 
in the studies. In healthy adults, a chronic caffeine consumption of up to 400 mg a day is generally 
regarded as safe;(26, 27) in the case of caffeine abuse the daily dosage exceeded this level and 
resulted in psychosis.(19) Individuals who are sensitive to caffeine, pregnant women, and people 
with mental or psychiatric disorders and disabilities (e.g. individuals with dementia) might be 
more susceptible(28) and experience adverse effects at a much lower dosage. In the studies in 
the present review, this might be why some of the participants showed a change in behavior that 
was attributed to caffeine.
A second reason for the absence of a consistent effect might be the differences in study popula-
tions. Although all studies included patients with dementia, some of the studies included only 
patients with dementia and behavioral symptoms(Golden et al., 2015; Ginsburg and Weintraub, 
1976; Kromhout et al., 2017). However, there was no consistent effect of caffeine on behavior in 
the studies that included only patients with dementia and behavioral symptoms, nor in the stud-
ies that included patients with dementia with and without behavioral symptoms. This suggests 
other factors contribute to the effect of caffeine on behavioral symptoms.
Another reason for the absence of a consistent effect might be the way that neuropsychiatric 
symptoms are reported. In the present review, with the exception of the case report, all studies 
used a version of the NPI to assess neuropsychiatric symptoms. The NPI consists of 12 neuro-
psychiatric symptoms (hallucinations, delusions, agitation/aggression, dysphoria/depression, 
anxiety, irritability, disinhibition, euphoria, apathy, aberrant motor behavior, sleep and night-time 
behavior change, and appetite/eating change) of which the severity and frequency are rated and 
multiplied to create a symptom score.(16) The NPI implies that neuropsychiatric symptoms tap 
from one underlying latent variable construct, thus representing a single underlying disorder, 
where the level of severity is measured as a sum score. The questions in the NPI-NH have the 
same content as the questions of the NPI but have been rephrased for the nursing home popu-
lation. (16, 29) Caffeine is known to have heterogeneous effects, potentially increasing several 
neuropsychiatric symptoms (e.g. agitation, anxiety, sleep disorders) and decreasing others (e.g. 
depression or apathy), both measured with the NPI(-NH). Therefore, a net neutral result could be 
based on the total NPI(-NH) score, whereas important insights might be derived by analyzing the 
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effects on neuropsychiatric symptoms in individual patients. This implies that larger studies are 
required on the effects of caffeine on individual neuropsychiatric symptoms.
In healthy adults, the negative effects of caffeine on sleep are thought to be caused by antago-
nizing the adenosine (A1 and A2) receptors in the brain.(13) Similar to the effects in healthy adults, 
caffeine was found to negatively impact sleep in some patients with dementia.(22, 25) However, 
surprisingly, in some patients the use of caffeine seemed to improve circadian rhythm(23) and 
sleep.(21) This positive effect of caffeine on sleep was also found in a 71-year-old man with a 
sleeping problem unresponsive to sedatives, who slept soundly after a cup of strong coffee before 
bedtime.(30) The author suggested that sleeping problems could have been caused by confusion. 
The consumed coffee could diminish the confusion by increasing attention and therefore have a 
positive effect on sleep. In the present review, no data were available on the amount of confusion 
of older patients with dementia who responded positively to caffeine,(21, 23); however, due to 
their illness, confusion might have played a role.
Another possible mechanism is the neurobiological changes in adenosine receptors, as A1 
receptor density reduces and the A2 receptor expression increases during the progression of Al-
zheimer dementia.(31) The A1 receptor inhibits a cascade of effects which promote ‘wakefulness’, 
while the A2 receptor stimulates several mechanisms which induce ‘sleepiness’.(32) By antagoniz-
ing both A1 and A2 receptors, caffeine impairs sleep. However, due to the different changes in 
receptor expression during disease progression, this effect might differ between healthy adults, 
patients with a mild dementia, and patients with severe Alzheimer dementia. In the treatment of 
dementia, the same paradox has been suggested, i.e. as in early dementia, an adenosine agonist 
might improve cognitive function and, as the disease progresses, adenosine antagonists have a 
more positive effect.(33) Therefore, caffeine may have a positive effect on sleep in patients with 
severe dementia, unless the diuretic effect of caffeine awakens them.
In adults, the effects of caffeine on behavior differ between individuals and can be influenced 
by genetics, expectations, frequency of use and tolerance developed. Generally, if there are ef-
fects, the individual regulates their caffeine consumption to minimize the adverse effects (12) or 
maximize the positive effects.(10) However, patients with dementia (especially institutionalized 
patients) cannot always modulate their caffeine consumption for their own benefit. Therefore, 
caretakers need to know the prior caffeine use/preferences of their patients and, in the case 
of behavioral symptoms, actively assess whether these might be attributable to caffeine use. 
However, this may not be easy and involves considering that something as common as caffeine 
(often used on a daily basis) can have both a positive or negative impact on complex behavior and 
neuropsychiatric symptoms in patients with dementia.
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ConCLusIon
This systematic review found no consistent effect of caffeine administration on neuropsychiatric 
symptoms in patients with dementia. Further research on the effects of caffeine on individual 
neuropsychiatric symptoms in patients with dementia is therefore warranted. However, there 
were indications that caffeine can both induce and reduce neuropsychiatric symptoms and 
sleeping difficulties in individual patients with dementia. Since ingestion of caffeine is an easily 
adaptable intervention, it is recommended to include caffeine consumption in the individualized 
approach of neuropsychiatric symptoms in patients with dementia.
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Since nursing home populations are diverse and often underrepresented in medical research, 
physicians in these homes need to assess the applicability of the limited research for the indi-
vidual patient. Research rarely focuses on simple everyday interventions, such as caffeine, despite 
that in healthy adults caffeine is known to influence behavior. Although behavioral symptoms in 
patients with dementia are frequent in nursing homes, the effects of caffeine on the behavior of 
older patients with dementia is not well researched. Therefore, this study aims to i) assess the 
relation between caffeine and behavioral symptoms in older patients, and ii) create an educa-
tional innovation of evidence-based medicine (EBM) training for elderly care physicians (ECPs). 
The study protocol is presented here.
Methods:
This study is a prospective multicenter cohort study and embedded in the Dutch ECP training pro-
gram. Trainees collect data from their own patients, based on medical records and interviews with 
nursing staff. Patient characteristics, nutritional data (including caffeine), functional status (e.g. 
functional comorbidity index), cognition (e.g. global deterioration scale), behavioral symptoms 
(e.g. Neuropsychiatric Inventory, Apathy Evaluation Scale and Minimum Data Set Depression Rat-
ing Scale) and social information are collected at baseline and at 2-months post-baseline. None 
of the instruments used places any burden on the patients. All data entered in the dataset are 
anonymized. Univariate analysis is used to assess the relation between caffeine and behavior, and 
multivariate analysis will correct for potential confounding factors. A subgroup analysis will assess 
the relation between caffeine and behavioral symptoms in patients with dementia. Trainees can 
formulate their own research questions and apply appropriate statistical techniques to answer 
their questions. During the entire study, all trainees are supervised by senior researchers and a 
professor.
Discussion:
This is the first large-scale study to assess the relation between caffeine and behavioral symptoms 
in older patients in nursing homes, with the aim to identify a potential simple intervention to deal 
with a complex problem. This study is part of an educational innovation of EBM training for ECPs 
which integrates EBM training, research and clinical practice.
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bACkGround
The vast majority of older people in the Netherlands live at home, with or without home care. If the 
demand for care exceeds the potential of home care, admission to a nursing home might be required. 
In the Netherlands, because the demand for care is the main reason for nursing home admission, 
this results in a heterogeneous population. Also, in Dutch nursing homes a differentiation is made 
based on the type of care, e.g. most older people with moderate to severe dementia are admitted to 
a specialized psychogeriatric ward, whereas physically disabled older people are generally admitted 
to a somatic ward. However, this differentiation is not absolute, as cognitive disorders are also com-
monly seen in patients on somatic wards. Moreover, besides the main diagnosis, since most patients 
have multiple comorbidities this tends to make nursing home populations even more diverse.
Dutch nursing homes not only employ nursing staff but also have their own medical, paramedi-
cal and psychosocial staff. The nursing home population requires a readily available medical gen-
eralist for all types of medical questions, as well as a specialist in the specific needs of the geriatric 
patient (1, 2), e.g. geriatric diseases, advanced care planning, behavioral symptoms and geriatric 
rehabilitation. Medical care in Dutch nursing homes is provided by elderly care physicians (ECPs), 
a medical specialty unique to the medical world.
The 3-year specialist training program for ECPs takes place in three Dutch universities and consists 
of three training periods in an educational nursing home, three internships, and a theoretical course 
lasting 100-120 days. Evidence-based medicine (EBM) is taught during the theoretical course. Cur-
rently, the EBM training of the ECP training at Leiden University Medical Center comprises: 1) several 
lectures on the basics of research and critical reading, 2) the writing of three Critically Appraised 
Topics (CATs) (3, 4) with questions initiated by the trainees themselves, and 3) participation in a 
group of ECP trainees to analyze an existing dataset and present the results to their peers. Teaching 
EBM is essential to create lifelong learners who can critically appraise information and assess the 
applicability of this information for the individual patient.(5) This applies, in particular, to elderly care 
medicine, due to the underrepresentation in medical research of frail elderly persons and nursing 
home residents. Although classroom teaching of EBM improves knowledge, clinically integrated 
teaching not only improves knowledge but also related skills, attitude and behavior.(6) Compared to 
traditional teaching, a blended learning approach is more effective in improving the attitude towards 
EBM and results in a higher self-reported use of EBM in clinical practice.(7) The EBM training program 
is regularly evaluated and updated to maintain a state-of-the-art program. Our latest innovation is 
the integration of a prospective cohort study assessing the relation between caffeine and behavioral 
symptoms, and the EBM training program; this is described in the study protocol presented here.
Of all patients admitted to Dutch nursing homes, ≥ 50% are diagnosed with cognitive disorders 
or dementia. In patients with dementia behavioral symptoms are often the main reason for nurs-
ing home admission, often due to the heavy burden placed on the caregivers (8), resulting in a 
high demand for care. In addition, behavioral symptoms lower the patient’s quality of life.(9) 
Behavioral symptoms are present in ≥ 80% of patients with dementia in a nursing home.(10, 11) 
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In patients with dementia the etiology of behavioral symptoms is complex and thought to be mul-
tifactorial.(12) To manage these symptoms, national guidelines recommend a detailed analysis 
of the patient, including contributing physical, psychological, social and environmental factors.
(12) Moreover, the intervention on behavioral symptoms is complex. Despite that many phar-
macological (13, 14) and psychosocial interventions have been studied,(15, 16) no standardized 
solution is available and all interventions targeting behavioral symptoms must be tailored.(15, 17) 
A customized, stepwise intervention, including not only analysis of the contributing factors but 
also the psychological and psychosocial unmet needs, has proven effective in targeting behavioral 
symptoms in patients with dementia.(18)
The Dutch national guideline on behavioral symptoms in patients with dementia mentions 
caffeine consumption as a possible contributing factor.(12) However, this conclusion is not based 
on research on patients with dementia or on patients in nursing homes. To date, the only study 
available on caffeine and behavioral symptoms in older patients with dementia in nursing homes 
is a small observational study showing an association with apathy, and an inverse association with 
aberrant motor behavior and caffeine consumption.(19) On the other hand, the effect of caffeine 
on behavior in adults has been widely investigated. Reviews show that normal caffeine consump-
tion in healthy adults increases alertness,(20-22) attention (20-22) and cognitive function (20, 
21), elevates mood (21) and reduces fatigue (22). In higher dosages (usually ≥ 300 mg) caffeine 
is known to increase anxiety,(21, 22) induce psychotic or manic symptoms (21) and impair sleep 
(22). These effects differ between individuals, and people normally adjust their consumption of 
caffeine based on their own experienced (non-)beneficial side-effects.(21, 22) However, institu-
tionalization and cognitive disorders tend to impair the ability to self-adjust caffeine consump-
tion. Based on research among healthy adults, in older patients with dementia in nursing homes 
both a positive or a negative influence of caffeine consumption on behavioral symptoms can be 
expected. However, additional research in larger study populations is needed to gain more insight 
into the effects of caffeine consumption in older people.
The purpose of this study is two-fold. The primary aim is to assess the relation between caffeine 
and behavioral symptoms (e.g. apathy and agitation) in older patients in nursing homes and to 
assess factors contributing to this relation. The second aim is to create an educational innovation 
of EBM training for ECPs, leading to a new EBM curriculum which stimulates trainees’ interest in 
research and integrates research into clinical practice. The study protocol is presented here.
meThods
study design
This study is a prospective multicenter cohort study, embedded in the ECP training program dur-
ing the theoretical course. In the new EBM program several improvements will be made. First, 
the basics of research and critical reading will be taught using classroom activities (lectures and 
Chapter 4 | A study protocol and evidence-based medicine training program
60
part-task practice) and online learning. Second, each trainee will participate in a complete medical 
study and this study will be embedded in their clinical practice. Writing three CATs remains part of 
the program. The result is a complete EBM curriculum with research skills introduced in manage-
able parts, a blended learning approach, and integration of the EBM program in clinical practice.
setting and study population
All trainees are asked to collect data from their own patients, thereby making every educational 
nursing home a possible center of study. As the maximum capacity of the ECP training program 
at Leiden University is 26 new trainees/year, a maximum of 26 nursing homes can participate 
in the study per year. The contracted educational nursing homes are situated in the southern/
mid-western part of the Netherlands.
As the population in nursing homes is highly diverse, a more homogeneous study population 
was desired, but without limiting the study population to a specific ward or unit; this would allow 
every trainee, irrespective of their training period, to participate. Therefore, to create a more 
homogeneous study population, a ‘ward transcending’ factor was chosen, i.e. diabetes mellitus 
type I and II. In European nursing homes, 21.8% of patients in nursing homes are diagnosed with 
diabetes mellitus.(23) A trainee on a full-time contract is supposed to provide medical care for 
50-80 patients. For this study, trainees were asked to include all patients under their care who 
had a diagnosis of diabetes (type I or II); no other inclusion criteria were applied. All participants 
and educational nursing homes received adequate oral and written information about the study.
ethical approval
The study protocol was approved by the Medical Ethics Committee of the Leiden University Medi-
cal Center. In accordance with Dutch legislation, a full review procedure by the Medical Ethics 
Committee was not deemed necessary because, in an observational study, no rules of conduct 
are imposed and no patients are subjected to any (medical) acts. Therefore, no formal written 
consent was required from the participants.
study procedure
As this prospective multicenter cohort study is embedded in the ECP training program, all data 
will be collected by ECP trainees who participate in the study for three years. In the first year 
of training, data are collected and research questions formulated, the second and third years 
are used to analyze/interpret the data and formulate conclusions (preferably in the form of an 
article). During the entire EBM training program, supervision is provided by senior researchers 
(MP, ME) and a professor in elderly care medicine (WA) from the Department of Public Health 
and Primary Care.
Currently, the study comprises a baseline measurement (T0) and a second measurement 
2-months post-baseline (T1). In the near future, a third measurement (T2, 4-months post-
baseline) will be added to the program.
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Trainees identify all patients under their care who have diabetes and assess them using a given 
set of instruments (see below). After assessment, the data are entered in a secure online platform 
(NetQ Healthcare) by the trainees. If any data are missing, the senior researcher contacts the 
trainee to complete the data. The title page, including (amongst other data) the name of the pa-
tient, are filed separately at the Department of Public Health and Primary Care. Only anonymized 
data remain in the dataset. The dataset is stored on a secure location at the same department, 
managed by the scientific staff. After trainees have formulated a research question, they are only 
provided with data required to answer their question.
Assessment instruments
All data used in the present study are part of data collected for routine/usual care in the nursing 
home. Data are collected by trainees, based on medical records and interviews with the nursing 
staff. The data are gathered according to the Somatic, Activities of daily living, Social, Psycho-
logical and Communication (SASPC) system, a problem-oriented system for multidisciplinary 
care,(24) which creates a complete overview of the patient. The components of the SASPC system 
are similar to those of the Comprehensive Geriatric Assessment (CGA): medical v. somatic; psy-
chosocial vs. social and psychological; and functional limitations vs. activities of daily living and 
communication. Although both the CGA and the SASPC are regularly used in the Netherlands, the 
SASPC system is more often used in nursing homes.
Only reliable and validated instruments are used to collect the data. None of the instruments 
burdens or bothers the patient in any way. The instruments used are described below (Table 1).
Table 1: The assessment instruments used.
Instrument T0* T1* T2*
somatic Patient characteristics X X X
Height, weight and body mass index X X X
Functional comorbidity index X X X
Medication X X X
Nutritional data X X X
Minimum Data Set Resident Assessment Instrument – subscale pain X X X
functional status/ activities of 
daily living
Barthel index X X X
Functional ambulation categories X X X
social Date of admission to nursing home X X X
Marital status X X X
Psychological Global deterioration scale X X X
Neuropsychiatric Inventory – Nursing Home edition X X X
Minimum Data Set Depression Rating Scale X X X
Apathy evaluation scale X X X
Communication Vision X X X
* T0: baseline; T1: 2 months post-baseline; T2: 4 months post-baseline (although not currently part of the study, this 
measurement will soon be added)
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Somatic
General patient characteristics are registered, including information on advanced care planning 
and medication, as well as specific diabetes-related information as blood pressure, heart rate, 
height, weight and (if present in the records) the serum hemoglobin, serum glycated hemoglobin 
(Hba1C) and kidney function (MDRD/GFR). Nutritional data are gathered on caffeine consump-
tion (recorded six times a day: the observed number of cups of coffee/tea/cola consumed, and 
the way the coffee was brewed), food consistency, and energy-enriched diets.
The Functional Comorbidity Index (FCI) is a comorbidity index which has physical function as the 
outcome of interest. The FCI contains 18 diseases and conditions: arthritis, osteoporosis, asthma, 
COPD, angina, congestive heart failure, prior heart attack, neurological diseases, prior stroke or 
transient ischemic attack, peripheral vascular disease, diabetes, upper gastrointestinal disease, 
depression, anxiety, visual impairment, hearing impairment, low back pain and obesity. The total 
score ranges from 0 (absence of comorbidity) to 18 (highest number of comorbid illnesses).(25)
The presence of pain in the last 7 days is scored using the subscale of the Minimal Data Set 
Resident Assessment Instrument (MDS RAI).(26) If pain was present, the frequency and intensity 
were also registered on a 2 and 3-point Likert scale, respectively.
Additionally, the presence of a urinary tract infection in the last 7 days was registered.
Functional status/activities of daily living
The modified Barthel index (BI)(27) measures mobility and dependency in activities of daily living 
(ADL) and records (using 10 items) the ADL of each patient. Total score ranges from 0 (completely 
dependent) to 20 (complete functional independence). When used for older people, the BI has a 
high inter-rater reliability for the total score, and a fair to moderate agreement for the individual 
items.(28)
The dependency of gait is classified using the Functional Ambulation Categories (FAC).(29) The 
FAC requires observation of gait over various slopes and surfaces, after which a rating ranging 
from 0 (non-functional ambulation) to 5 (independent) is given. The use of walking aids is allowed.
Social
The date of admission to the nursing home and marital status are registered.
Psychological
The stage of cognitive decline is assessed using the Reisberg Global Deterioration Scale (GDS).(30) 
The GDS consists of seven stages ranging from 1 (no cognitive decline) to 7 (very severe cognitive 
decline/severe dementia).
Behavioral symptoms are measured using the Dutch version of the Neuropsychiatric Inventory-
Nursing Home edition (NPI-NH).(31-33) The NPI-NH assesses 12 different types of behavioral 
symptoms: delusions, hallucinations, agitation, depression/dysphoria, anxiety, euphoria/elation, 
apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, nighttime distur-
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bances and appetite/eating change. Both severity and frequency are rated on a Likert scale. For 
each symptom, a score is calculated by multiplying the severity and frequency scores. The total 
score is calculated by summing the symptom scores. Symptom scores range from 0-12, and the 
total score ranges from 0-144. The NPI-NH is a valid and reliable tool for Dutch nursing home 
settings and has a high inter-rater agreement.(33)
Depressive symptoms are measured with the Minimum Data Set Depression Rating Scale 
(MDS-DRS), an observation-based instrument to screen for depression in nursing home residents.
(34) The MDS-DRS consists of seven items which are scored irrespective of the assumed cause: 0 
(indicator not exhibited in the last 30 days), 1 (indicator of this type exhibited at least once in last 
30 days and up to 5 days a week) or 2 (indicator of this type exhibited daily or almost daily (6-7 
days a week)). Total score ranges from 0-14. At a cut-off point score of 3 the MDS-DRS has a 91% 
sensitivity and 69% specificity compared to the DSM-IV diagnosis of depression.(34)
Apathy is measured using the Dutch Apathy Evaluation Scale-Clinician version (AES-C).(35, 36) 
It consists of 18 items, all scored on a 4-point Likert scale (not at all characteristic, slightly char-
acteristic, somewhat characteristic, and very characteristic). A higher score represents greater 
apathy. Total score ranges from 18-72 and a score ≥ 38 is indicative of apathy.(36, 37) The AES-C 
has a high interrater reliability and can be used to discriminate between apathy and depression.
(36)
Communication
Because patients with diabetes are at greater risk for eye problems, the last measured visual 
acuity by an ophthalmologist is obtained from the medical records.
statistical analysis
The relation between caffeine and behavioral symptoms will be assessed using several tech-
niques. Descriptive analysis is used for patient characteristics, behavior characteristics, disease 
characteristics and caffeine consumption; univariate analysis to identify the relation between 
caffeine and behavioral symptoms; and multivariate analysis is used to correct for potential 
confounding factors, such as age, gender and stage of cognitive decline. To assess the relation 
between caffeine and behavioral symptoms in patients with dementia, subgroups according to 
the Reisberg GDS will be created and analyzed.
The trainees will use statistical techniques appropriate to their research questions. All data are 
analyzed using the Statistical Package for Social Science version 23.0.
dIsCussIon
This study assesses the relation between caffeine and behavioral symptoms among older patients 
in nursing homes. If caffeine proves to be related to (several types of) behavioral symptoms, a 
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relatively simple intervention (such as adjusting caffeine consumption) might prove beneficial and 
improve the patient’s quality of life. This study also serves to innovate the EBM training program 
in ECP training.
Few studies have examined the effects of caffeine among older patients. To our knowledge, this 
study (embedded in the ECP training program) will comprise the largest group of older patients 
with data on their behavior, cognition and caffeine consumption. To ensure that all trainees 
can participate, all patients with diabetes are included. However, as all trainees are engaged in 
data collection this might affect reliability; therefore, only validated instruments are used which 
(mostly) have a high level of interrater agreement.
Behavioral symptoms are not limited to dementia, but can be present in patients with all types 
of cognitive and/or psychiatric disorders. Due to the inclusion of all patients with diabetes, the 
complete spectrum of cognitive disorders (ranging from mild to severe) will be represented in this 
study. The consumption of both caffeinated and decaffeinated coffee is associated with a dose-
responsive decreased risk of type 2 diabetes.(38, 39) Therefore, in theory, high coffee consumers 
might be underrepresented in the present study. However, the underlying mechanism of the 
inverse association between coffee and diabetes is not yet fully understood (38-40); moreover, 
this inverse association is reported to be present only in patients aged ≤ 60 years.(41)
Based on caffeine research in healthy adults, (20-22) both an increase and decrease in be-
havioral symptoms in patients with dementia can be expected. A small observational study on 
a group of older patients with dementia, reported that an increase in caffeine consumption is 
associated with a decrease in apathy, and an increase in aberrant motor behavior and sleeping 
difficulties (19); this confirms both the positive and negative effects of caffeine. Due to this dual 
effect, the overall group total of behavioral symptoms might result in a neutral score, falsely sug-
gesting that caffeine has no relation with behavioral symptoms. Therefore, detailed analysis of 
not only the group total, but also the individual items, is appropriate.
Although EBM is considered essential in practicing medicine, obstacles in teaching EBM in-
clude: insufficient interest and/or limited time of trainees and faculty, lack of trainee research 
skills, absence of a research curriculum, and inadequate funding.(42) As this study is embedded 
in the EBM training program, the above obstacles related to teaching EBM have been tackled. 
Integration with clinical practice is beneficial for the trainees (6, 43) and might also improve the 
knowledge and attitude of current ECPs.(44)
In conclusion, this is the first large study to focus on caffeine and behavioral symptoms in older 
patients in nursing homes. Embodiment of this study in the ECP training program serves to update 




ADL: Activities of daily living
AES-C: Apathy Evaluation Scale-Clinician version
BI: Barthel Index
COPD: Chronic Obstructive Pulmonary Disease
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition
EBM: Evidence-Based Medicine
ECP: Elderly Care Physician
FAC: Functional Ambulation Categories
FCI: Functional Comorbidities Index
GDS: Global Deterioration Scale
MDRD/GFR: Modification of Diet in Renal Disease formula for Glomerular Filtration Rate
MDS-DRS: Minimum Data Set – Depression Rating Scale
MDS RAI: Minimum Data Set Resident Assessment Instrument
NPI-NH: Neuropsychiatric Inventory – Nursing Home edition
SASPC: Somatic, Activities of daily living, Social, Psychological and Communication
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Although behavioral changes are common in nursing home residents with dementia and caffeine 
is known to influence behavior in healthy adults, the effects of caffeine on the behavior of persons 
with dementia has received little attention. In this study we assessed the relationship of caffeine 
and behavioral symptoms in older persons with dementia.
Design:
A multicenter sub-cohort study embedded in the Elderly Care Physicians (ECP) training program.
Setting:
Dutch nursing homes associated with the ECP training program.
Participants:
A total of 206 individuals with both diabetes and dementia resident in Dutch nursing homes.
Measurements:
Trainee ECPs collected data on caffeine consumption, cognition and behavioral symptoms using 
the NPI-NH, MDS-DRS and AES-C. Data on factors known to influence behavior in persons with 
dementia (e.g. marital status, kidney function, urinary tract infection and medication) were also 
collected.
Results:
Of the 206 participants, 70% showed behavioral symptoms. An increase in caffeine consumption 
was associated with a decrease in the presence of behavioral symptoms in the NPI-NH cluster 
affect and NPI-NH item agitation. Caffeine consumption groups also differed on the presence of 
disinhibition and depression. In addition, the severity of dementia influenced agitation, anxiety 
and the clusters affect and psychomotor.
Conclusion:
In a large group of older persons with dementia resident in nursing homes, a low daily consump-
tion of caffeine was associated with greater behavioral symptoms.
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InTroduCTIon
By our definition, behavior is an ‘observable response to a particular situation’. The mechanisms 
underlying behavior are mostly unconscious, complex and are probably shaped by a range of 
factors. The consumption of coffee and other caffeinated beverages is known to influence be-
havior. In healthy adults, reviews show that normal caffeine consumption increases alertness and 
attention(1-3), elevates mood(2), and reduces fatigue.(3) At higher dosages (usually ≥ 300 mg) 
caffeine is known to increase anxiety,(2, 3) induce psychotic or manic symptoms(2), and impair 
sleep.(3) Effects differ between individuals and people usually adjust their caffeine consumption 
to minimize adverse effects.
In persons with dementia, behavioral symptoms that may include aggression, agitation, or 
anxiety are seen in almost all cases at some point during the disease. These symptoms are also 
referred to as behavioral problems, behavioral and psychological symptoms of dementia’ (BPSD) 
or neuropsychiatric symptoms. Behavioral symptoms accompanying dementia have a negative 
impact on a person’s quality of life(4), place a heavy burden on caregivers,(5) result in a high 
demand for care, and are therefore often the reason for nursing home admission.(6) Over half of 
all persons admitted to Dutch nursing homes are diagnosed with cognitive disorders or dementia, 
and behavioral symptoms are present in more than 80% of persons with dementia resident in 
nursing homes.(7, 8)
A review of the limited evidence currently available on caffeine consumption in persons with 
dementia found inconsistent data regarding the effects of caffeine administration on neuropsy-
chiatric symptoms: high caffeine consumption was associated with less apathy in one study; in 
another study coffee therapy decreased the Neuropsychiatric Inventory (NPI) total score and 
eliminating caffeine lowered the total NPI; in a third study caffeine consumption improved sleep 
in some persons and eliminating caffeine improved sleep in others.(9) Current data are therefore 
ambiguous and inconclusive, as caffeine was reported to both induce and reduce neuropsychi-
atric symptoms and sleeping difficulties in individual persons with dementia. Based on caffeine 
research in healthy adults (1-3) and a review in persons with dementia (9), both an increase 
and decrease in behavioral symptoms in persons with dementia can be expected. Specifically, 
we hypothesized that caffeine consumption may increase anxiety and aberrant motor behavior 
in persons with dementia, while decreasing apathy. Therefore, in this study we explore 1) the 
relation between caffeine consumption and behavioral symptoms in persons with dementia, and 
2) the influence of dementia severity on any possible relationship.
meThods
This multicenter cohort study was embedded in the Dutch Elderly Care Physician (ECP) training 
program, and was conducted according to a study protocol published in detail earlier.(10) Briefly, 
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during the ECP training program, trainees spend three periods at an educational nursing home 
and gain experience on several types of wards (e.g. a dementia special care unit or rehabilita-
tion unit). To allow every trainee to participate, the study population could not be limited to 
individuals living in a specific type of ward, which means a diagnosis of dementia could not be 
an inclusion criterion as this would have excluded some trainees. To create a homogenous study 
population that would allow inclusion of all trainees, a ward transcending inclusion measure was 
chosen that was not associated with behavioral symptoms in persons with dementia.(10) After 
careful deliberation, diabetes was chosen and ECP trainees were asked to include, during their 
first year of training, all persons under their care who had a diagnosis of diabetes (type I or II); no 
other inclusion or exclusion criteria were applied. Persons were included over three consecutive 
years, resulting in three cohorts. Data was collected based on medical records and interviews 
with nursing staff. None of the instruments used placed any burden on study subjects, and the 
study protocol was approved by the Medical Ethics Committee of the Leiden University Medical 
Centre. In accordance with Dutch legislation, a waiver was given for a full review procedure by the 
Medical Ethics Committee because no rules of conduct were imposed and no participants were 
subjected to any (medical) intervention.
data collection
Patient characteristics (age, gender) and known factors influencing behavior in persons with de-
mentia (e.g. marital status, kidney function, presence of a urinary tract infection and medication) 
were collected from the medical records.
In interviews with nursing staff, the presence of pain, the modified Barthel Index (BI), the stage 
of cognitive decline, caffeine consumption and behavioral symptoms were measured. The pres-
ence of pain in the last 7 days was scored using the subscale of the Minimal Data Set Resident 
Assessment Instrument (MDS RAI).(11)
The modified BI(12) measures mobility and dependency in activities of daily living (ADL) and re-
cords (using 10 items) the ADL of each patient. Total scores ranges from 0 (completely dependent) 
to 20 (complete functional independence). When used in older people, the BI has a high inter-
rater reliability for the total score, and a fair to moderate agreement for the individual items.(13)
The stage of cognitive function was assessed using the Reisberg Global Deterioration Scale 
(GDS), which consists of seven stages ranging from 1 (no cognitive decline) to 7 (very severe 
cognitive decline/severe dementia). (14)
To measure caffeine consumption the number of cups of coffee, tea and cola consumed was 
observed and recorded six times a day. The amount of caffeine in coffee differs depending on how 
coffee is brewed: the longer the coffee grounds are in contact with water, the more caffeine is 
released. Therefore, the manner of coffee preparation was also noted, and based on the brewing 
method, ingested caffeine was estimated in milligrams (mg) as in previous studies (15, 16) and 
subjects divided into three groups based on low, normal or high caffeine consumption.
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Behavioral symptoms were measured using the Neuropsychiatric Inventory-Nursing Home edition 
(NPI-NH)(17-19), depression was measured with the Minimum Data Set Depression Rating Scale 
(MDS-DRS)(20) and apathy with the Dutch Apathy Evaluation Scale-Clinician version (AES-C).(21, 22)
The NPI-NH assesses the severity and frequency of 12 different types of behavioral symptoms: 
delusions, hallucinations, agitation, depression/dysphoria, anxiety, euphoria/elation, apathy/
indifference, disinhibition, irritability/lability, aberrant motor behavior, nighttime disturbances and 
appetite/eating change. For each symptom, an item score can be calculated by multiplying the se-
verity and frequency scores. The total score is the sum of all the symptom scores. Symptom scores 
range from 0-12, and the total score ranges from 0-144. The NPI-NH items can also be combined in 
clinically meaningful clusters: cluster psychosis (delusions and hallucinations), cluster psychomotor 
(agitation, disinhibition and irritability) and affect (depression and euphoria).(17) The NPI-NH is a 
valid and reliable tool in Dutch nursing home settings and shows high inter-rater agreement.(17) 
Individual NPI-NH items with a score of > 4 are considered clinically relevant.(7, 23)
The MDS-DRS is an observation-based screening instrument for depression in nursing home 
residents.(20) It consists of seven items that are scored 0-1-2, irrespective of the assumed cause, 
and total scores range from 0-14. At a cut-off score of 3, the MDS-DRS has a 91% sensitivity and 
69% specificity compared to the DSM-IV diagnosis of depression.(20)
Apathy was measured using the 18 item AES-C.(21, 22) Total scores range from 18-72 and a 
score ≥ 38 is indicative of apathy.(21, 22) The AES-C has a high inter-rater reliability and can be 
used to discriminate between apathy and depression.(21)
statistical analysis
The three cohorts were merged, checked for duplicate cases and a subgroup created containing 
only persons with dementia. Patient characteristics, behavioral characteristics, disease characteris-
tics and caffeine consumption were then defined using descriptive analysis. Differences in caffeine 
consumption between persons with and without clinically significant behavioral symptoms were 
analyzed for total NPI-NH score, the MDS-DRS and the AES-C. The NPI-NH clusters and individual 
NPI-NH items were also analyzed if a behavioral symptom was present in at least 15% of partici-
pants. A chi-squared test was used to analyze categorical outcomes and the Cochran-Armitage test 
was used to analyze trends. A Pearson correlation coefficient was computed to assess the relation-
ship between daily ingested caffeine (in mg) and the NPI-NH total score. Finally, multiple logistic 
regression, with robust standard error estimation adjusting for clustered design (General Estimated 
Equations (GEE)), was used to correct for potential confounding factors. Per outcome two models 
were considered: 1. Based on the variables age, gender and stage of cognitive decline; 2. The 
variables age, gender and stage of cognitive decline together with of any of the following variables 
that were significantly related to the specific outcome (the use of psychotropic medication, marital 
status, Barthel Index total score, the presence of pain, cohort and kidney function). A p value less 
than 0.05 was considered statistically significant. Statistical analyses were performed using the IBM 
Statistical Package for Social Sciences (SPSS) version 23, with additional analysis in R+.
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resuLTs
The dementia subgroup consisted of 206 persons with a Reisberg GDS of > 4 and a mean age of 
82 years. Over half were female (59%) and three quarters were resident in a dementia special 
care unit. The average consumption of caffeine was within the normal range at 237mg a day, as 
high consumption is defined as over 300mg a day. The majority (70%) of participants had clinically 
relevant behavioral symptoms (defined as one or more NPI-NH item with a score of > 4). Patient 
characteristics are presented in table 1.
Table 1. Patient characteristics for all persons with dementia, and for persons with dementia with and without 




Age (mean + SD) 82 years + 9 82 years + 8 81 years + 10
Gender (n=206) (n=139) (n=59)
Female 59% 61% 56%
Male 41% 39% 44%
Medication: number of prescriptions (mean + SD) 7 + 3 7 + 3 8 + 3
Psychotropic medication (n=199-202) (n=132-135) (n=58-59)
Antidepressant 20% 25% 14%
Antipsychotics 16% 19% 9%
Benzodiazepine 19% 24% 14%
Antiepileptic 9% 8% 14%
Kidney function (MDRD/GFR (mean + SD)) 62ml/min + 23 61ml/min + 21 63ml/min + 23
Pain in the last 7 days (n=206) (n=139) (n=59)
Yes 30% 34% 24%
No 70% 66% 76%
Caffeine consumption (median (range)) 237mg/day (0-680) 230mg/day (0-595) 285mg/day (12-680)
Functional status/activities of daily living
Barthel Index (median (range)) 8 (1-20) 8 (1-20) 11 (1-20)
Social
Department (n=206) (n=139) (n=59)
Dementia special care unit 76% 78% 75%
Somatic department 24% 22% 25%
Marital status (n=206) (n=139) (n=59)
Married 27% 28% 27%
Widowed 54% 55% 53%
Divorced 5% 4% 10%
Single 13% 14% 10%
Psychological
Reisberg GDS (n=206) (n=139) (n=59)
4 17% 14% 27%
5 35% 30% 46%
6 33% 37% 22%
7 16% 19% 5%
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A small negative correlation was seen between the total NPI-NH score and the daily consump-
tion of caffeine (r = -0.179, n = 142, p = 0.033*). No associations between caffeine consumption 
and apathy, as measured with the NPI-NH and the AES-C, were found.
An increase in caffeine consumption was associated with a decrease in the presence of clini-
cally relevant behavioral symptoms in the NPI-NH cluster affect and the NPI-NH item agitation. A 
difference was also noted between caffeine consumption groups for the presence of disinhibition 
(measured with the NPI-NH) and depression (according to the MDS Depression Rating Scale), but 
without evidence of a trend. Other NPI-NH items, the NPI-NH clusters and the AES-C did not differ 
between caffeine consumption groups. (See table 2).
Table 2. Behavioral symptoms and caffeine consumption
behavioral symptoms n Caffeine consumption (%) statistics
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We found no association between caffeine consumption and the total NPI-NH score when 
adjusted for the ‘in nursing home’ clustered design (p = 0.572). However, there were percentage 
differences for the NPI-NH clusters psychomotor and affect, the NPI-NH items agitation, disinhibi-
tion and anxiety, and the MDS-DRS with respect to caffeine consumption (adjusted for model 
variables and for the clustered design). Persons with dementia and diabetes consuming high 
amounts of caffeine were less likely to have symptoms in the NPI-NH affect cluster and the NPI-NH 
item agitation compared to those consuming low amounts of caffeine. The group consuming low 
amounts of caffeine was less likely to show agitation than the group consuming normal amounts 
of caffeine. Persons consuming normal amounts of caffeine had fewer symptoms on the NPI-NH 
psychomotor cluster, and the NPI-NH items disinhibition and depression (measured with both 
the NPI-NH and the MDS), compared to those consuming low amounts of caffeine (see table 3 for 
model 1 and table 4 for model 2).
The presence (%) of behavioral problems differed with the severity of dementia. In both the 
adjusted models, persons with moderately severe and severe dementia had a higher percentage 
of psychomotor behavior and agitation (p values 0.005, 0.043, 0.001 and 0.001, respectively). In 
the second model (in which the variables age, gender and stage of cognitive decline were entered, 
with addition of any variables significantly related to a specific outcome) behavioral symptoms 
in the NPI cluster affect and the NPI item anxiety were highest in persons with mild dementia (p 
values 0.046 and <0.000, respectively).
Table 2. Behavioral symptoms and caffeine consumption (continued)
behavioral symptoms n Caffeine consumption (%) statistics
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3.77, p = 0.152 0.064
NPI-NH: Neuropsychiatric Inventory – nursing home edition, MDS-DRS: minimal data set – depression rating scale, 
AES-C: Apathy evaluation scale – clinicians edition
* significant
** statistical assumptions were not met for chi-square due to low number of persons with the symptoms, therefore 
the results of a two-sided Fisher’s Exact test in R+ is also given
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Table 3. Model 1. Log regression analyses with robust SE estimation adjusting for in nursing home clustered 
design (General Estimated Equations).
behavioral symptom n Gee Adjusted % of behavioral problems by 
caffeine consumption (%(CI))
normal vs low 
(or (CI))
high vs low 
(or (CI))
p ** Low normal high
NPI-NH
Cluster Psychomotor 146 0.5 (0.2-1.0)* 0.6 (0.3-1.0) 0.040* 62 (48-73) 42 (28-57) 48 (36-59)
Cluster Affect 146 0.7 (0.3-1.5) 0.3 (0.1-0.7)* 0.025* 42 (31-55) 33 (17-55) 18 (9-32)
Agitation 146 0.3 (0.1-0.9)* 0.3 (0.2-0.5)* 0.000* 49 (38-60) 25 (13-42) 23 (17-32)
Depression 145 0.6 (0.2-1.8) 0.6 (0.2-2.1) 0.630 22 (12-37) 15 (6-32) 14 (6-31)
Anxiety 146 1.1 (0.6-2.2) 0.3 (0.1-1.2) 0.028* 23 (14-35) 25 (15-39) 10 (4-23)
Apathy 145 0.9 (0.4-1.8) 0.7 (0.3-1.8) 0.773 27 (15-43) 24 (13-40) 21 (11-36)
Disinhibition 146 0.1 (0.0-0.6)* 0.6 (0.2-2.2) 0.001* 25 (13-43) 4 (2-11) 17 (8-35)
Lability 146 0.6 (0.3-1.4) 0.7 (0.4-1.2) 0.313 34 (26-43) 25 (13-43) 25 (17-36)
Other
AES-C 147 1.6 (0.7-3.9) 2.2 (0.8-6.4) 0.327 56 (38-73) 68 (48-83) 74 (56-86)
MDS 145 0.3 (0.1-0.7)* 0.7 (0.4-1.3) 0.015* 35 (23-50) 14 (8-23) 28 (18-40)
NPI-NH: Neuropsychiatric Inventory – nursing home edition, MDS-DRS: minimal data set – depression rating scale, 
AES-C: Apathy evaluation scale – clinicians edition
Variables entered in the model: caffeine consumption, Reisberg GDS, gender and age
* statistically significant (p value < 0,05)
** p value for difference in percentage of behavioral problems with respect to caffeine consumption group, adjusted 
for the variables entered in the model
Table 4: Model 2. Log regression analyses with robust SE estimation adjusting for in nursing home clustered 
design (General Estimated Equations).










Cluster Psychomotor a,b,c,d,e,f 140 0.4 (0.2-0.9)* 0.6 (0.4-1.1) 0.049* 59 (38-76) 36 (17-61) 47 (27-67)
Cluster Affect a,b,c,d,e 139 0.5 (0.3-1.2) 0.2 (0.1-0.5)* 0.002* 47 (34-60) 32 (16-54) 17 (9-30)
Agitation a,b,c,d,e 140 0.3 (0.1-0.9)* 0.3 (0.2-0.5)* 0.000* 50 (37-62) 24 (11-44) 24 (17-32)
Depression a,b,c,d,e,f 139 0.3 (0.1-0.8)* 0.4 (0.1-1.8) 0.056 22 (9-45) 9 (3-21) 10 (4-26)
Anxiety a,b,c,d,e,g 134 1.5 (0.6-4.0) 0.3 (0.1-1.6) 0.089 18 (10-31) 26 (13-44) 7 (2-24)
Apathy a,b,c,d,g 139 0.9 (0.4-1.9) 0.8 (0.3-2.5) 0.933 23 (11-42) 21 (10-39) 21 (10-37)
Lability a,b,c,d,h 146 0.7 (0.3-1.7) 0.8 (0.4-1.4) 0.633 34 (25-45) 27 (13-46) 29 (19-40)
Other
AES-C a,b,c,d,g,I,j 141 1.7 (0.6-4.6) 1.8 (0.4-8.0) 0.567 48 (29-69) 62 (44-76) 63 (32-86)
MDS a,b,c,d,e 140 0.3 (0.1-0.7)* 0.6 (0.3-1.3) 0.017* 36 (21-54) 13 (7-22) 27 (17-39)
NPI-NH: Neuropsychiatric Inventory – nursing home edition, MDS-DRS: minimal data set – depression rating scale, 
AES-C: Apathy evaluation scale – clinicians edition
The variables entered in the model are indicated with a superscript letter behind the behavioral symptom: a Caffeine 
consumption, b Reisberg GDS, c gender, d age, e the use of psychotropic medication, f marital status, g Barthel Index 
total score, h the presence of pain, i cohort, j kidney function
* statistically significant (p value < 0.05)
** p value for difference in percentage of behavioral problems with respect to caffeine consumption group, adjusted 
for the variables entered in the model
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dIsCussIon
In this cross-sectional study of nursing home residents with dementia, we found a number of 
associations between caffeine consumption and behavioral symptoms, including consistent dif-
ferences between caffeine consumption groups for behavioral symptoms in the NPI-NH cluster 
affect, the NPI-NH items agitation, disinhibition and depression, and depression as measured 
with the MDS-DRS. Persons consuming low amounts of caffeine were most likely to have behav-
ioral symptoms. Furthermore, some behavioral symptoms differed between persons with mild, 
moderate, moderately severe and severe dementia.
Few studies to date have considered the role of caffeine consumption in behavioral symptoms 
in persons with dementia, and most previous studies have methodological flaws that preclude 
consistent conclusions.(9) The results of the present study in accordance with some studies but 
contradict others. In the present group of older persons with diabetes and dementia, a higher 
total NPI-NH score initially correlated with lower caffeine consumption, but this association 
disappeared when adjusted for the clustered design and potential confounders. A Japanese study 
reported a significant drop in the total NPI score in a group that received coffee therapy compared 
to a control group.(24) In a single subject trial of a patient with a high caffeine use and high 
total NPI score, a decrease was seen during the decaffeinated period.(16) However, neither study 
corrected for potential confounders.
Regarding caffeine consumption and apathy in persons with dementia, both negative(15) and 
positive associations have been reported, with elimination of caffeine reportedly leading to a 
decrease in apathy.(25) The present study found no association between caffeine consumption 
and apathy, as measured by the NPI-NH and the AES-C. In both of the earlier studies apathy was 
the least frequent behavioral symptom and the studies were conducted in dementia special care 
units. In the present study persons with dementia were included both from somatic departments 
and from dementia special care units, and apathy was one of the most frequently noted be-
havioral symptoms. In our experience, persons with dementia assigned to somatic departments 
are more likely to have vascular dementia than other forms of dementia. Apathy is known to 
be more common in persons with vascular dementia than in patients with Alzheimer’s disease, 
possibly as a direct result of damaged subcortical circuits, (26) and may therefore explain the 
above mentioned differences and lack of association in the present study.
Perhaps the most interesting finding in this study was that high caffeine consumption was 
consistently associated with lower agitation. This is in contrast to earlier studies, which found 
no relation between caffeine consumption and agitation in persons with dementia.(15, 25) In 
addition, two single subject trials including individuals consuming very high amounts of caffeine 
found either no effect or a negative effect of caffeine on agitation.(16)
As the present study was cross-sectional, causality could not be determined and the identi-
fied association might be due to agitated persons spending less time consuming coffee (or other 
beverages) rather than caffeine itself reducing agitation in other persons with dementia. Agitation 
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is known to increase as dementia progresses,(27) and in our sample agitation was more common 
in persons with (moderately) severe dementia. Therefore, lower caffeine consumption could also 
be due to other dementia-related factors. Nevertheless, a dose-dependent effect of caffeine on 
aggression in animal models follows an inverted-U shaped curve, with lower aggression at very 
low and very high doses of caffeine.(28) This finding suggests that the relationship between agita-
tion and caffeine consumption may be more complex than simple positive or negative individual 
associations.
The group with normal caffeine consumption had fewer depressive symptoms compared to 
the group consuming low amounts of caffeine. Studies of depression and caffeine consumption 
are scarce, but two reviews (2002 and 2018) both suggested that moderate to intermediate 
consumption of caffeine is beneficial for depression in healthy adults.(3, 29) The same pattern is 
visible in our study, as the group with high caffeine consumption had a higher level of depression 
than the normal caffeine consumption group. Caffeine is a known receptor antagonist of the 
A1 and A2a adenosine receptors,(29) which are involved in cognition, motivation and emotions 
(amongst other effects). However, at high doses caffeine may no longer behave as an adenosine 
receptor antagonist,(30) potentially explaining the U-shaped association between depression and 
caffeine consumption.
To the best of our knowledge, this investigation is the largest study of behavior, cognition, 
and caffeine consumption in older persons conducted to date. The cross-sectional design and 
embedding in the Dutch Elderly Care Physician training program made it possible to study such 
a large group. However, this design has two limitations that should be mentioned. Firstly, data 
were collected by ECP trainees in an educational setting rather than by professional researchers 
in a study setting. Nonetheless, data collection was supervised by a senior researcher and there 
is no reason to suppose that an ECP trainee would collect incorrect data. Secondly, the choice for 
a ‘ward transcending’ inclusion criterion (diabetes) allowed all trainees to participate irrespective 
of department, but resulted in inclusion limited to persons with diabetes. As there is no evidence 
of a relationship between caffeine consumption and diabetes in persons over 65 years of age, and 
no known relationship between diabetes and behavioral symptoms, the results of this study are 
likely to be valid for nursing home residents with dementia without diabetes.
In conclusion, a low daily consumption of caffeine was associated with behavioral symptoms in 
a large group of nursing home residents with dementia and diabetes. To determine causality, in-
tervention studies are warranted. Due to the highly individualized effects of caffeine on behavior, 
a study with individualized outcome measurements is preferred before firm recommendations 
can be made for specific groups. However, as caffeine consumption is an easily adaptable inter-
vention, it can be considered as a potentially beneficial component in an individualized approach 
to neuropsychiatric symptoms in persons with dementia.
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The work presented in this thesis aims to expand knowledge on the relationship between caffeine 
consumption and behavior in persons with dementia. As stated in the general introduction, we 
hypothesized that caffeine consumption and behavior likely interact in persons with dementia 
and that both an increase and a decrease in behavioral symptoms would be possible. The known 
stimulatory effects of caffeine suggest the possibility of an increase in behavioral symptoms 
by suppressing fatigue and inducing restlessness in persons with dementia. However, caffeine 
consumption might also reduce behavioral symptoms in persons with dementia by improving 
concentration, lessening overstimulation or due to the social aspect of caffeine consumption.
The studies in this thesis support the hypothesis outlined above, as both positive and negative 
relationships were found in the course of our studies:
• In our observational pilot study (chapter 1), a negative correlation was found between 
caffeine consumption and apathy and aberrant motor behavior (AMB), whereas a positive 
correlation was found between late evening consumption of caffeine and getting up in older 
persons with moderate to severe dementia resident in a dementia special care unit.(1)
• In two single subject trials (chapter 2), reduction of caffeine consumption decreased several 
behavioral symptoms, including agitation/ aggression, irritability, AMB and general restless-
ness, in one 85-year-old woman with Alzheimer’s disease but did not influence the aggressive 
behavior of another person diagnosed with mixed type dementia.(2)
• In a thorough systematic review of literature (chapter 3) we found indications that caffeine 
can both induce and reduce behavioral symptoms in persons with dementia. However, no 
consistent effect of caffeine consumption on behavioral symptoms could be demonstrated.(3)
• In our large cross-sectional study (chapter 5), behavioral symptoms (e.g. agitation, disinhibi-
tion and depression) were most common in persons with a low caffeine consumption.
To answer the question ‘can coffee use influence the behavior of persons with dementia’, we will 
first take a closer look at the most recent pathophysiological insights concerning the main target 
receptors of caffeine in the brain and what is currently known about the role these receptors play 
in the changing brain of a person with dementia. Insights into caffeine, adenosine receptors (AR) 
and dementia changed during the course of our research and our findings contribute to these 
changes. We will then explore the possible influences of caffeine consumption and behavioral 
symptoms in persons with dementia. To fully appreciate our results, several methodological con-
siderations will also be discussed, after which we round up with the clinical implications of our 
findings and suggestions for further research.
CAffeIne And AdenosIne reCePTors In The brAIn
Caffeine has several targets in the brain, of which the most commonly discussed is the nonselective 
antagonism of adenosine receptors. Caffeine also known to interfere with dopamine, serotonin, 
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norepinephrine, epinephrine, acetylcholine and glutamate neurotransmission in the brain,(4, 5) 
to induce direct release of intracellular calcium, to inhibit cyclic nucleotide phosphodiesterase 
and to block GABA receptors.(4, 6) However, the doses required to achieve the latter effects (on 
calcium, cyclic nucleotide phosphodiesterase and GABA) are beyond toxic levels in humans.(6) 
Caffeine also has a weak affinity for benzodiazepine receptor binding sites and can counteract or 
alter the effect of benzodiazepines on human behavior,(7) although it has been suggested that 
the level of caffeine needed to antagonize the benzodiazepine receptors is likely toxic in humans 
and the modifying effect of caffeine on benzodiazepines might therefore actually be mediated 
via the adenosine receptors.(7) Taken together, these data suggest that antagonism of adenosine 
receptors in the brain is likely to be the primary mechanism of action of caffeine.(6)
Adenosine has several regulatory functions, but the most important are thought to be main-
tenance of energy homeostasis in the body and neuromodulation in the brain.(8, 9) Within the 
brain, adenosine is known to affect the release of neurotransmitters, neuronal excitability, synap-
tic plasticity and neuroinflammation.(9, 10) Four distinct adenosine receptors have been identi-
fied to date, adenosine (A)1, A2a, A2b and A3, each of which shows different expression patterns 
in brain regions and synaptic sites and each has different effects.(8, 9) The A1 and A3 receptors 
both have inhibitory effects, while both forms of the A2 receptor are stimulatory.(9) Only the A1, 
A2a and A3 receptors are present in the brain. The A1 receptors are mostly present in the cortex, 
hippocampus and cerebellum,(9) and presynaptically-distributed A1 receptors inhibit the release 
of glutamate, dopamine, serotonin and acetylcholine,(8) whereas postsynaptically-distributed 
A1 receptors inhibit neuronal signaling and reduce excitability.(8) The A2a receptors are mainly 
concentrated in the striatum and are only weakly present in the cortex and hippocampus.(9) 
The A3 receptors have a moderate presence in the hippocampus and cerebellum and are less 
prominent elsewhere in the brain.(9)
The exact function of the ARs is still unknown, but the various roles of the AR subtypes are 
currently being unraveled using so-called knockout mice (KO; living mice in which a part of the 
DNA is artificially switched off).(9) (See table 1). However, in humans the ARs appear to have both 
overlapping and unique roles. A recent review of the role of ARs in mood and anxiety disorders(8) 
concluded that agonism of the A2a receptors increases depression-like symptoms, while agonism 
of the A1 receptors has antidepressant effects. In anxiety, agonism of A1 receptors had anxio-
lytic (reducing) effects, whereas antagonism of A1 receptors or non-specific antagonism of ARs 
induces anxiety-related behaviors.(8) The distribution of ARs in the brain, differences in synaptic 
sites and multiple subtypes of ARs together provide many different pathways through which brain 
functions can be influenced by AR antagonism. This complexity makes characterization of the 
specific functions of ARs more difficult.(9)
As discussed above, caffeine is a known non-selective AR antagonist that impacts several AR 
subtypes, showing effects that differ depending on acute or chronic use(11) and low or high 
doses.(12) The effects of caffeine are primarily meditated through the A1 and A2a receptors, 
and major differences and even conflicting effects on ARs are seen following either acute or 
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chronic intake of caffeine.(11) Chronic consumption of caffeine has various neuroprotective ef-
fects which are characterized by upregulation of the A1 receptors but stable expression of the 
A2a receptors,(11) resulting in a shift in the balance of ARs.(11) Our study participants(1, 2, 13) 
were probably chronic coffee consumers, but the influence on behavior of the expected shift 
in AR balance is still too poorly understood to allow clear prediction of expected outcomes. 
However, we know that the number of ARs in the brain normalizes between one and five days 
after cessation of caffeine consumption.(6) This rapid normalization suggests that the participants 
in the single subject trials(2) probably had a normalized AR balance within a week of the shift 
to decaffeinated coffee. Their behavior over the following two weeks during which alternately 
decaffeinated or caffeinated coffee was consumed might represent behavior uncolored by the ef-
fects of chronic caffeine intake. These single subject trials could therefore, inadvertently, provide 
additional insight into the potential roles of ARs in behavior. In one subject, no relation between 
caffeine consumption and behavior could be detected. However, in the other subject an increase 
in behavioral symptoms consisting mainly of aggression and aberrant motor behavior was seen 
as caffeine was reintroduced during the second week. Interestingly, the item scores for these 
behavioral symptoms following the decaffeinated washout period were lower compared to the 
baseline (caffeinated) score prior to washout, suggesting that antagonism of the A1 receptor 
might be the main driver of behavior in this person with dementia. However, as this observation 
was confined to a single individual, firm conclusions cannot be drawn regarding the impact of the 
ARs on behavior and further research will be necessary to explore these intriguing preliminary 
insights.
In addition to the differences that occur following acute or chronic use, caffeine may also have 
biphasic effects, with differences in effect apparent between low and high doses.(12) In chapter 
5, this biphasic effect was observed for the NPI item disinhibition and depressive symptoms 
as measured with the MDS-DRS. The exact mechanism underlying this biphasic effect is as yet 
unknown, but several mechanisms have been proposed(12):
1. Differences may be due to individual variation, some of which appear to have a genetic origin.
(12)
2. The effects of low dose caffeine are mediated through mechanisms that are distinct from 
those of high dose caffeine. The inhibition of phosphodiesterase (PDE) has been suggested as 
a possible mechanism controlling some of the effects of caffeine.(12)
Table 1. Changes in behavior shown in AR knock-out (KO) mice(9)
behavior A1 ko mice A2a ko mice A3 ko mice
Mood Reverse behavioral 
despair/antidepressive
More behavioral despair
Anxiety More anxiety-like behavior (Inconsistent) Some anxiety, but attributed to hyperactivity
Aggression Increased aggression Increased aggression
Psychomotor 
activity




3. The biphasic effect might be due to the involvement of A3 receptors. In both A1 receptor 
knockout mice, A2a receptor knockout mice and control mice high dose caffeine influences 
behavior in a similar manner. However, A3 receptor knock-out mice showed a different re-
sponse to caffeine than control mice at a dose that failed to produce a difference in A1 and 
A2a knock-out mice. The authors conclude that the A3 receptors may be responsible for the 
effects of caffeine following high dosages.(9)
Although antagonism of ARs in the brain is thought to be the primary mechanism of action of 
caffeine, nevertheless the involvement of different subtypes of ARs, the effect of AR upregulation 
with chronic caffeine use, the influence of the ARs at different brain sites and the dose response 
effects of caffeine all remain unresolved. A clear description of the mechanisms through which 
caffeine influences behavior, even in healthy persons, is therefore still lacking.
AdenosIne reCePTors And The ChAnGInG brAIn In Persons wITh 
demenTIA
Dementia is a neurodegenerative disorder and the expression of the adenosine receptors is 
known to change with disease progression. In persons with Alzheimer dementia, the A2a recep-
tors are increased in the hippocampus and cerebral cortex,(10, 14) A1 receptor density is reduced 
by 40-60% in the hippocampus and striatum, (10, 14) and both A1 and A2a receptor levels in the 
frontal cortex are increased in either the early or advanced stages of Alzheimer’s.(15) It has been 
suggested that A1 receptors may play a role in the pathogenesis of Alzheimer dementia, and that 
modulating the A2a receptors might have neuroprotective effects during progression.(14) While 
the impact of changes in the expression of ARs on behavior during the progression of dementia 
is presently unknown, the fact of changes suggests that the influence of caffeine is also likely to 
change.
CAffeIne And behAvIor In Persons wITh demenTIA
Taking into account the results of the studies presented in this thesis, the known functions of 
ARs and the changes that occur during the progression of dementia, the relationship between 
caffeine consumption and behavior in persons with dementia is either immensely complex or 
very straightforward. Previous studies have reported associations between behavioral symptoms 
and caffeine consumption in persons with dementia, but the direction and size of effects varied 
to such an extent that if we were to pool results, the net effect would be close to zero. The 
straightforward explanation is that all study results are coincidental or biased, and there is no 
consistent association between caffeine use and behavior.
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A more complex and nuanced explanation is that the relationship between caffeine and 
behavioral symptoms is multifactorial, and factors influencing associations most likely include 
personal differences, dosage, chronic use, progression of neurodegenerative diseases and other 
multimorbidities. We discuss these factors in more detail below.
The effects of caffeine differ, even among healthy adults, and these differences are known to 
affected by many factors, for example the polymorphisms in cytochrome P450 CYP1A2, which 
metabolizes caffeine, and adenosine A2a receptor, which is the target of caffeine in the brain and 
is thought to be responsible for most of the behavioral effects.(16) There is also no evidence to 
suggest that individual sensitivities to caffeine disappear in the event of dementia. Consequently, 
and similarly to healthy adults, some individuals with dementia will be unaffected by caffeine 
while others will have sleeping difficulties after just a single cup of coffee in the afternoon. This 
pattern was also seen in the single subject trials.(2) Healthy adults tend to adjust their personal 
caffeine consumption to minimize the adverse effects or maximize the benefits, but persons with 
dementia are unlikely to be able to self-adjust caffeine consumption and may therefore be more 
prone to suffer adverse effects.
As discussed, the effect of caffeine on behavior is generally attributed to antagonism of ad-
enosine receptors, but when consumed in high doses caffeine may no longer act as an adenosine 
antagonist(12), whereas low doses might not reach the threshold for effect. Depending on specific 
circumstances, the dose-dependent effects of caffeine might follow both a straight line and a U 
(or inverted U)-shaped curve, as described in chapter 5.
Different effects on behavior are seen upon chronic versus acute consumption of caf-
feine,(17-19) an outcome most likely due to upregulation of the A1 receptors shifting the balance 
of ARs.(11) In addition to the upregulation or ARs due to chronic consumption, dementia is a 
neurodegenerative disease that also may influence adenosine receptors in the brain, leading to 
effects of caffeine that may differ amongst healthy persons, persons with mild dementia and 
persons with severe dementia.(3)
To summarize, current evidence suggests that the individual, the disease (dementia), the inter-
vention (caffeine) and behavior may all be interdependent, resulting in a very complex relation-




The complexity of the relationship between caffeine and behavioral symptoms in dementia can 
also be explored using Kitwood’s equation. Kitwood stated that the symptoms of dementia can 
be understood as an interaction between neurological impairment (NI), physical health (H), psy-
chological factors (P), personal biography (B) and the social context [social psychology] (SP):(20)
D = NI + H + B + P + SP
NI ↓ =
A recent systematic review concluded that consumption of coffee, tea and caffeine or 
higher plasma caffeine levels may protect against the onset of dementia, but the evi-
dence was too limited to draw conclusions regarding an effect on the progression of dementia.
(21) Although an exact mechanism has yet to be identified, it has been suggested that caffeine 
might directly reduce amyloid beta production in the brain(22) and thus have a direct influence 
on neurological impairment in persons with dementia.
H ↕ =
Caffeine has widespread pathophysiological effects on the body, both positive and 
negative. On the positive side, due to adenosine antagonism and a vasoconstricting 
effect, caffeine is known to reduce pain, especially when taken in addition with regular analgesics.
(23) In our cross-sectional study (chapter 5), pain was tested as a possible confounder and was 
found to influence the association between caffeine and the NPI-item lability. Caffeine is also 
known to induce cardiac arrythmias, especially in persons with preexisting cardiac comorbidity. 
The physical health of a person with dementia can be influenced by caffeine but depending on the 
comorbidity, caffeine might improve or worsen physical health.
P ↕ =
Mood and anxiety are among the psychological factors that can impact the behavior of 
a person with dementia. In some adults, consumption of high doses of caffeine can lead 
to increased anxiety,(18) but a similar relationship has not been found in studies of persons with 
dementia(3) (as presented in chapter 3 of this thesis). In our latest study (presented in chapter 5 
of this thesis) the group with high caffeine consumption had less anxiety compared to the group 
with low caffeine consumption, when corrected for the clustered design. In humans, both high 
and low caffeine consumption seems to be associated with anxiety. Caffeine is a non-selective 
adenosine antagonist, and the adenosinergic system has a role in both the etiology and treatment 
of depression and anxiety.(8) Studies in rodents have helped unravel specific roles of the adenos-
ine receptors in anxiety, as knockout of the A1 and A2a adenosine receptors increases anxiety-like 
behavior in mice(8), while overexpression of the A2a receptor in mice resulted in a decrease in 
exploratory behavior (also indicative of an increase in one aspect of anxiety).(24) Just as A2a 
knockout and A2a overexpression both result in behavioral changes indicative of increase anxiety 
in mice, human consumption of caffeine results in a similar pattern of anxiety-related changes.
In chapter 5, we also found that depressive symptoms were lower in the group with normal caf-
feine consumption compared to the group with low caffeine consumption, an outcome consistent 
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with findings in healthy adults.(18) (25) Although the exact mechanisms are not (yet) known, it 
is clear that caffeine can have a direct influence on depressive symptoms and anxiety in persons 
with dementia.
SP ↑ =
The effects of caffeine are not limited to the physical and psychological, the consump-
tion of caffeine-containing beverages also has a strong social aspect, as the social 
consumption of coffee is the customary way to ingest caffeine. Having a cup of coffee together 
with others, sitting quietly, chatting or reading a paper are all regular social rituals. According to 
the Unmet Needs Model by Cohen-Mansfield, unmet needs for social contacts or social activities 
can lead to behavioral symptoms in persons with dementia.(26) Both the Dutch(27) and the UK 
Alzheimer foundations(28) advise caregivers to take social activities into account when faced with 
behavioral symptoms. Although having a cup of coffee together is not specifically mentioned, it 
can act as a calming social ritual as suggested in one study.(29)
D = NI + H + B + P + SP D = NI + H + B + P + SP D = NI + H + B + P + SP
Example 1. Less neurological impairment 
and pain, improved mood and a strong 
social effect of caffeine consumption 
leading to less behavioral symptoms.
Example 2. Sleeping difficulties due 
to caffeine consumption, resulting in 
agitated behavior during the day.
Example 3. No changes in health or 
other factors in the equation due to 
genetic factors.
Accordingly, and depending on genetic variation, age, gender, sensitivity to caffeine, severity of 
dementia and any comorbidity, the equation of dementia might be influenced in specific ways by 
the consumption of caffeine (see examples).
meThodoLoGICAL ConsIderATIons
Although the studies presented in this thesis are very different in design, size and level of evi-
dence, they all share certain strengths.
Firstly, these studies were the first of their kind to study the effects of caffeine on behavior in 
persons with dementia. During the progression of the studies that make up this thesis, a stepwise 
design was used that started with a small pilot study and a single subject trial to test whether 
the hypothesis was sufficiently robust to justify the later, larger studies. The combination of both 
small and large studies provided important insights into the complexity and treatment possibili-
ties of caffeine in the behavioral symptoms of dementia.
Secondly, these pragmatic studies were all conducted with frail older persons representing the 
reality of the nursing home resident, in contrast to most medical research that unfortunately 
excludes older persons with dementia or persons with multimorbidity, resulting in limited evi-
dence concerning this rapidly expanding group. In the pragmatic observational (chapter 1) and 
cross-sectional multicenter (chapters 4 and 5) studies the caffeine consumption was not altered 
or regulated. The results of these studies are based on normal caffeine consumption, instead of 
General discussion | 
92
the extremely high caffeine dosages regularly seen in caffeine research.(18, 30) Thus the influ-
ence of withdrawal is expected to be next to nothing. The conclusions from these studies can 
therefore be reliable extrapolated and offer directly applicable insights on caffeine consumption 
and behavioral symptoms in patients with dementia.
Thirdly, a common bias in food research is the recall bias. An example is smoking or alcohol 
consumption: participants (unconsciously) want to put themselves in a better light by underesti-
mating the number of cigarettes or liters of beer they consume. But the other way around is also 
prevalent, for example the overestimation of the amount of vegetables one consumes in a day. 
The recall bias is also seen in caffeine research.(31) However, in the three studies to chance of a 
recall bias is small as the amount of caffeine consumed was observed and noted during the same 
shift, not recalled later.
Lastly, most studies research high-tech, theoretical interventions aimed at tomorrows’ patients. 
Our studies of caffeine are unique in the sense that this is an intervention for todays’ patients and 
current patients with dementia will benefit from the results.
However, to fully understand the results the following weaknesses have to be taken into account.
Firstly, persons with dementia were treated as a single study population, even though de-
mentia is an umbrella term covering over 100 different diseases. Much is still poorly understood 
regarding the impact of disease on the brain in persons with dementia (a ‘black box brain’). As 
caffeine influences brain neurotransmitters, it is possible that effects of caffeine differ depending 
on a specific disease or its stage. In a larger study, subgroup analysis based on major causes of 
dementia could be conducted to test whether this hypothesis is valid.
Secondly, a wide variety of behavioral symptoms were included in these initial pilot studies, 
including scores for several total scales. As caffeine may both induce and reduce behavioral 
symptoms, symptom-specific follow-up research would be advisable, preferably tailored to the 
individual.
Thirdly, in chapter 5 we described the dose-dependent effects of caffeine might follow both a 
straight line and a U (or inverted U)-shaped curve. Although our results do not stand alone and 
the response threshold and receptor regulation can be an explanation for the observed effects, 
severe design errors like a differential misclassification error can also lead to a reversal of results. 
However, in the studies in this thesis the measurements of the caffeine consumption and the 
scoring of behavioral symptoms was done by different persons and at the moment of scoring the 
participant was not yet assigned to a specific group. Therefore, the chance a structural severe 
differential misclassification influenced the results of both of these studies is small. However, 
there is a risk of non-differential misclassifications like incorrectly quantifying the amount of caf-
feine consumed (e.g. by over- or underestimating the amount of coffee in a cup or the amount of 
caffeine in the coffee). During the studies these measurements were standardized were possible 
and the amount of caffeine was calculated based on the way the coffee was brewed. When the 
brewed method was unknown or there was no average caffeine level know for the brew method, 
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the caffeine consumed could not be estimated. It is therefore possible the amount of caffeine is 
over- or underestimated, however, the best guess possible was made.
Fourthly, there are factors that are both associated with caffeine consumption and with behav-
ioral symptoms in patients with dementia. In the multi-center cross-sectional study corrections 
were made for all know confounders. Due to the possible widespread influence of caffeine as 
shown in the paragraph ‘Kitwood’s equation’ there is a potential of residual confounding. A 
lot of possible confounders were included in the study (see chapter 4 for the complete list of 
measurements). Several psychosocial and other lifestyle factors were not included in the study. 
All of the participants lived in nursing homes and had, at least at the moment of study, a similar 
general lifestyle. However, it is possible different nursing homes have different styles and thereby 
influencing both caffeine consumption and behavior. Although we did not correct for lifestyle as a 
single confounder, a correction for the nursing home (the clustered design) was made. However, 
residual confounding cannot be ruled out completely.
Finally, parts of this study were embedded in the Elderly Care Training Program. This program 
made it possible to collect data on cognition, caffeine consumption and behavior in a larger 
number of elderly nursing home residents (as described in chapter 4(13) and 5), but also required 
us to limit inclusion to persons with diabetes and thereby limit the range of possible inclusion. As 
far as we now there is no relation between diabetes and caffeine consumption or diabetes and 
behavior in elderly patients, so the selection of participants was unrelated to their behavior and 
their caffeine consumption. The results of the study are most likely also valid for patients with 
dementia without diabetes. However, this design has one important potential weakness: is the 
risk that trainees are more prone to make mistakes in data collection than trained researchers. 
However, as the trainees were supervised by senior researchers and subsample cross-checking 
was conducted to identify potential mistakes, we believe that any risk was minimal. Therefore, we 
stand by the results of this study and consider them reliable.
Despite these possible limitations, the studies described in this thesis provide unique insights 
into the relationship between caffeine and behavioral symptoms in persons with dementia, and 
have clinical implications that could benefit today’s patients (discussed below).
CLInICAL ImPLICATIons
As mentioned above, if one assumes that any association will necessarily be unidirectional and 
consistently linear, one might draw the conclusion that there is no relation between caffeine and 
behavioral symptoms in persons with dementia and, therefore, no clinical implications. However, 
this thesis provides data to support the argument that there is a relationship between caffeine 
and behavioral symptoms in persons with dementia, and this relationship differs per person, is 
dose-dependent, and changes with age and the presence of dementia.
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However, even if we accept the relationship between caffeine and behavioral symptoms in 
persons with dementia as proven, there will still be some individuals in whom the consumption of 
caffeine has no effect on behavioral symptoms. Conversely, some individuals with dementia will 
show a (strong) response following consumption of caffeine. As caffeine consumption is an easy-
to-manage intervention against the background of hard-to-manage behavioral symptoms that 
place a major burden on caregivers and reduce the quality of life of the person with dementia, it 
is advisable to take caffeine consumption into account when planning a stepwise, individualized 
approach to behavioral symptoms. While caffeine isn’t one of the ‘usual suspects’ in behavioral 
symptoms, there is enough evidence to argue that it should at least be included in the line-up.
A stepwise, personalized approach to behavioral symptoms in persons with dementia should 
include a detailed analysis of the individual and their surroundings. In the diagnostic approach, 
we look for probable or possible contributory factors in a multidisciplinary journey into known 
behavioral symptoms such as pain, psychosis, infections, or over-stimulation, while also consider-
ing the unknown, unmet needs of a person who is incapable of communicating needs in any 
other way. The evidence is clear: caffeine is not just another ingredient in a drink. It should be 
included in the vocabulary of the professional as a possible influencing factor, similarly to over- 
and under-stimulation, toothache, constipation and miscommunication. If an analysis shows 
new agitation that started directly after admittance to a dementia special care unit and no other 
probable explanations are identified, a detailed analysis of the differences between home and 
nursing home might show a switch from decaffeinated to caffeinated coffee, suggesting that a 
switch to decaffeinated coffee is worth a try. Analysis might also show a significant decrease in 
coffee consumption on admission, in which case an increase in coffee consumption is also worth 
a try. It might also show that at home the person with dementia always went for a small walk in 
the garden after a coffee break. In terms of caffeine, analysis of behavioral symptoms involves not 
just asking ‘do you prefer your coffee black, or with milk or sugar?’ but taking into account all the 
nuances of coffee, such as ‘do you prefer filter or espresso, black, with milk or sugar, at what time 
would you like the coffee, with a newspaper or a conversation, etc.’
furTher reseArCh
In medical research, the ultimate proof of an intervention is a randomized controlled trial that is 
designed to prevent factors other than the intervention from influencing outcome by standard-
izing participants, measurements and the intervention itself.(32) This evidence-based method 
has been called into question, as it’s based on standardized situations which simplify reality and 
ignores the multifactorial nature of daily practice. To put the evidence into practice, nuances of 
the evidence are needed. Therefore, the Dutch Council for Public Health and Society recommends 
that evidence-based medicine should be extended to embrace the context of the person.(32) If 
we hold to standard evidence-based practice, confirmation of the relationship between caffeine 
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and behavior remains unlikely due to the complexity of this relationship. However, when the con-
text of the person is taken into account, a complex relationship between caffeine and behavioral 
symptoms suddenly becomes probable. We would therefore argue that the results concerning 
the effect of caffeine on behavior in persons with dementia warrant further research.
In our opinion both experimental and fundamental research into this subject is needed. At the 
moment, changes occurring in the brain of persons with dementia are poorly understood, but 
more research in this area could lead to potential new interventions for future patients with be-
havioral symptoms and dementia, perhaps also including more detailed insights into the effects of 
caffeine on the brain or even clues for additional interventions. However, persons with dementia 
who have behavioral symptoms today will clearly not benefit from these studies. These people 
require interventions now. The research detailed in this thesis shows that caffeine could be one 
such intervention but a clearer picture is needed. As changes to the brain and the sensitivity to 
caffeine of persons with dementia are both individual, a traditional randomized controlled trial 
will not suffice to provide clarity. The ideal design should include the context of the person, and 
cover both individual and group effects. An approach including the context of the patient could 
involve either a large series of single subject trials or a randomized controlled trial with goal 
attainment scaling. As stated in chapter 3, the single-subject trial is a randomized blinded study 
with one single patient. Usually it has a crossover design in which an intervention and a placebo 
both are tried multiple times to determine which is more beneficial.(33) It is seen as the ultimate 
proof for the individual patient(34, 35), especially if the intervention has shown individual varia-
tion in efficacy (35) like caffeine. Although a single single subject trial is the ultimate proof for a 
single patient, several single subject trials can be combined to estimate a population effect(33) 
and identify distinguishing features between those who benefit and those who do not benefit 
from the intervention.(35) Another practical element in this approach is that the single subject 
trials might differ slightly in design as long as the design is robust and the results are valid.(35) 
This means the design can be matched to the specific circumstances of the patient with dementia, 
the caffeine consumption and the behavioral symptoms involved, e.g. a longer washout period 
in patients with hepatic impairment or an extra crossover period. In an randomized controlled 
trial with goal attainment scaling, the design is standardized but for each participant a personal 
outcome (goal) is defined.(36) However, every goal is scored in a standardized way: a 5-point 
Likert scale ranging from ‘-2: much less than expected’ to ‘+2: much more than expected’). In both 
methods, the large series of single subject trials and the more traditional randomized controlled 
trial with goal attainment scaling, the outcomes are defined for a specific participant. In addition, 
in the single subject trials the design could also be slightly altered to fit a specific participant 
better. As both are some kind of randomized controlled trial, their ideal designs have several 
similarities but some remark differences. In the table the headlines of these two possible designs 
for further research are illustrated.
These study designs need to be worked out in more detail and several caffeine related chal-
lenges have to be specified. First, the way of measurement of caffeine has to be defined. To 
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determine the relation between caffeine consumption and behavior in patients with dementia, 
a continuous measurement of caffeine levels in combination with a continuous observation of 
behavior would yield the most precise results. The continuous measurement of caffeine levels 
bypasses the individual caffeine metabolism, but it does not surpass the individual ARs layout in 
the brain. So, we would know how much caffeine was in de blood during behavioral symptoms, 
but not how the brain is affected by the caffeine, so the added effect is limited. A single measure-
ment of plasma caffeine levels might be arrangeable in nursing homes, but the added value is 
even less due to the same reason. If the purpose of the study is to measure the clinical effect, 
then the observation of ingested caffeine is sufficient, cheap and practical. However, the second 
specification has to be the way the caffeine is ingested. Caffeine can be administered in different 
ways: by injections, capsules or cups of coffee (with or without added caffeine). If caffeine is given 
by injection or capsule, the dosage of caffeine is exact. The amount of caffeine in coffee differs 
between the coffee bean used, the way the coffee is made and several other factors. Depending 
on the study goal, the preferred way of administering the caffeine can differ. An intervention trial 
into the positive effects of caffeine would probably have more use for a standardized dosage 
Table 2. Overview of two different study designs for further research into the effect of caffeine consumption 
on specific behavioral symptoms in patients with dementia
study type series of single subject trials rCT with goal attainment scaling
Participants Patients with dementia who consume 
caffeine, and have behavioral symptoms 
in which caffeine is expected to have a 
positive or negative influence
Patients with dementia who consume 
caffeine, and have behavioral 
symptoms which are thought to be 
negatively influenced by caffeine 
consumption
estimated number of participants 
needed
60 120
randomisation ABBAAB Participants are randomized in two 
groups: intervention and control
study period 6 periods of a week each (length of periods 
adjustable to the participant)
Two-week baseline and two-week 
intervention period, followed by a two 
week return to normal
Intervention/ ‘A’ Caffeinated coffee and tea, in standardized 
cups and brew method
Decaffeinated coffee and tea, in 
standardized cups and brew method
Control/ ‘b’ Decaffeinated coffee and tea, in 
standardized cups and brew method
No adjustment in caffeine consumption
outcome measurements For each participant an individual target 
behavioral symptom is defined, including 
the scale or index used to score and the 
preferred outcome
Goals attainment scaling: a personal 
goal per participant and the 
standardized scoring system.
In addition, the NPI-NH for every 
participant once during every study 
period.
blinding Caffeine consumption and behavioral 
symptoms scored by different 
professionals.
Study period blinded for the participant 
and professionals.
Caffeine consumption and behavioral 
symptoms scored by different 
professionals.
Study group blinded for the participant 
and professionals.
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which can be easily administered like a capsule. A trial into the etiology of behavioral symptoms 
and the role of caffeine would benefit more by including to normal caffeine consumption, like 
cups of coffee. To make an estimated guess of the caffeine consumed, the cup size and the brew 
method have to be included in the design. The other effects of caffeine in the body also have to be 
taken into account: adding more caffeine can have physical effects confounding the results, which 
makes a continuation of normal caffeine use more appealing for research in the frail population.
If the methodological challenges into caffeine research, behavioral research and research in 
frail elderly patients with dementia are taken into account, there are several reliable and valid 
study designs possible for further research. However, to make the designs feasible in complex 
situations like elderly care a certain amount of pragmatism is needed for researchers.
ConCLusIon
This thesis suggests caffeine has a place in a detailed analysis of behavioral symptoms in persons 
with dementia. However, advice on the treatment of behavioral symptoms cannot be given for 
a group of persons with dementia. As always, this depends on the multidisciplinary analysis of 
contributing factors.
A simple question: a complex answer 
Coffee can influence behavior in persons with dementia, but most likely not in all persons, not in all situations and 
not all of the time; but it can have an influence. Therefore, it is recommended to consider caffeine as a possible 
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The word “dementia” derives from the Latin stem ‘demens’ and literally means ‘without mind.’ 
The medical term dementia covers over 100 diseases in which cognitive function deteriorates to a 
greater extent than seen in normal aging. Attention, planning, learning, memory, language, visual 
perception, spatial skills, social skills or other cognitive functions can all be affected. Patients with 
dementia can also display non-cognitive symptoms, e.g. aggression, agitation, anxiety, apathy, 
which are together referred to as behavioral symptoms. The etiology of behavior in patients with 
dementia is complex. Almost all patients with dementia will show behavioral symptoms at some 
point during the disease which decrease quality of life of the patient with dementia and place a 
high burden on informal caregivers. A higher caregiver burden often worsens the relationship be-
tween the caregiver and the patient with dementia, which in turn may increase the frequency and 
severity of behavioral symptoms. Quick and adequate management of behavioral symptoms in 
patients with dementia is necessary to prevent further harm for the patient, caregiver overload, 
avoidable nursing home admissions and avertible society costs.
To manage behavioral symptoms, the first step recommended in guidelines is the detailed 
analysis of the patients’ behavior, including contributory physical, psychological, social and envi-
ronmental factors, after which interventions can be formulated. Although there is some evidence 
pharmacological agents can decrease behavioral symptoms in patients with dementia, the clinical 
effect is small and there is a high risk of severe adverse effects and even death. Psychosocial 
approaches have also been widely studied. Approaches like behavioral management techniques 
or cognitive stimulation are proven reduce behavioral symptoms. But in the management of 
behavioral symptoms, no standardized solution is currently available. All interventions that target 
behavioral symptoms must be tailored to the individual. However, even in the individualized ap-
proach nutritional factors are not regularly included as a possible cause or intervention.
Caffeine has been used for several centuries to influence behavior and the effects of caffeine on 
behavior in adults have been widely researched. It is now widely accepted that moderate caffeine 
consumption in healthy adults increases alertness, attention and cognitive function. It also elevates 
mood and reduces fatigue. A high caffeine consumption increases anxiety, can induce psychotic or 
manic symptoms and impairs sleep. As these effects differ between individuals, people normally 
adjust their consumption of caffeine based on their personal experience of (non-)beneficial (side)
effects. Although the effect of caffeine on behavior in adults is widely accepted, the effect of 
caffeine on behavior in patients with dementia has not been properly investigated. As coffee is 
regularly consumed, widely available and most nursing homes do not have specific limitations or 
adjustments in the caffeine consumption of the residents, more insight in the relation between 
caffeine and behavior in patients with dementia is wanted.
Based on the known stimulatory effects of caffeine in healthy adults, it seems logical to assume 
that caffeine increases behavioral symptoms caused by general restlessness, anger and anxiety 
and increases sleeping difficulties during the night by suppressing fatigue in patients with demen-
tia. The sleeping difficulties can lead to greater daytime sleepiness and a reversion of circadian 
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rhythm in patients with dementia which in its turn can also increase behavioral symptoms (e.g. 
irritability).
However, the opposite can also be hypothesized: caffeine consumption may favorably impact 
behavioral symptoms by improving concentration and lessening overstimulation due to an 
increase in alertness. Another possible favorable mechanism is the social aspect of caffeine 
consumption as social activities in general can reduce behavioral symptoms.
Both hypotheses were considered equally strong, therefore the aim of this thesis was to inves-
tigate whether there is a relationship between caffeine consumption and behavioral symptoms 
in patients with dementia, and (if a relationship exists) to determine the direction of any effects.
This thesis consists of four studies conducted in a stepwise design. First, two different studies 
were done to explore the hypotheses. If these studies showed signs of validation of the hypoth-
eses, the second step would include more thorough research: a systematic literature review and a 
large multicenter cohort study. Chapter 1 describes the observational pilot study which was per-
formed to explore the possibility of a relationship between caffeine and behavioral symptoms in 
a group of elderly patients with dementia, with a focus on sleep, aggression, depression, anxiety, 
apathy, irritability and aberrant motor behavior. Over four days, these behavioral symptoms were 
measured using the Neuropsychiatric Inventory – Nursing Home edition (NPI-NH) and a sleep 
questionnaire, together with careful observation of caffeine consumption. In this sample of 29 
elderly persons with dementia living in a special care unit a negative correlation between caffeine 
consumption and apathy and aberrant motor behavior (AMB) was found and positively correlated 
with getting out of bed at night. No significant correlations were found between caffeine and ag-
gression, depression, irritability or anxiety. This exploratory study showed an association between 
caffeine consumption and some behavioral symptoms in a group of persons with moderately 
severe dementia.
Chapter 2 describes the second exploratory study. Because caffeine shows strong individual 
variation in effects on behavior in healthy adults, the second study was designed to examine 
the individual effects. In two persons with dementia, a high caffeine use and severe behavioral 
symptoms, caffeine consumption was regulated over a four-week period in a blinded crossover 
trial. The participants were served caffeinated or decaffeinated coffee in a predetermined order 
(C-D-D-C). Behavioral symptoms were then scored using the NPI-NH and the Cohan Mansfield 
Agitation Inventory (CMAI), with outcomes individualized per patient. Participant A was an 
85-year-old woman with Alzheimer’s disease and participant B was a 91-year-old women with 
mixed type dementia. Participant A had a decrease in her specific behavioral symptoms in the 
decaf weeks and a small increase on reintroduction of caffeine. In participant B no relation be-
tween caffeine and behavioral symptoms was found. This second study confirmed the association 
between caffeine and behavioral symptoms, but also showed the individual variation in effects.
The results of the two exploratory studies necessitated further research. Chapter 3 describes 
the thorough and systematic literature review which was conducted according to the Preferred 
Reporting Items for Systematic reviews and Meta-analysis (PRISMA) guidelines. The study proto-
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col is registered at PROSPERO. The research question was formulated as “Does caffeine or coffee 
consumption influence neuropsychiatric symptoms, e.g. agitation, aggression, apathy, irritability, 
in elderly patients with dementia?”. Six (medical) journal databases (Medline (PubMed), Embase, 
Emcare, Cochrane, PsychInfo and Web of Science) and gray literature (GLIN, Greylit, AACN Re-
search & Data center, WHO, OpenGray, HSO and Clinicaltrials.gov) were searched and more than 
4000 articles were screened for relevance by two reviewers. After screening for eligibility, only 
seven articles remained. The seven studies differed in almost all facets: study type (from a case 
report to a RCT), publication date (ranging from 1976 tot 2018), methodology (qualitative and 
quantitative), the way of administering caffeine (beverages to injections) and measuring behavior. 
Most of the studies had methodological issues and despite a thorough analysis, no consistent 
conclusions could be drawn regarding caffeine consumption and behavioral symptoms. However, 
in each trial, the behavior of some participants seemed to be influenced by caffeine consumption 
both in a positive and in a negative way.
As fourth and final study, a large multicenter cohort study was conducted with the aim of as-
sessing the possible relationship between caffeine and behavioral symptoms in a large group 
of nursing home residents with dementia. The three-year study was embedded in the Elderly 
Care Physicians training program, and trainees collected data on caffeine consumption, cognition, 
behavioral symptoms and social status. The study design is described in detail in chapter 4. To the 
best of our knowledge, these efforts resulted in the largest existing dataset on cognition, behavior 
and caffeine consumption amongst nursing home residents. In chapter 5 we discuss the results 
of a subgroup analysis of the persons with dementia. Just over 200 persons were included, of 
which 70% showed behavioral symptoms. People consuming low amounts of caffeine were most 
likely to have behavioral symptoms. Furthermore, some behavioral symptoms differed between 
persons with mild, moderate, moderately severe and severe dementia.
The general discussion starts with a closer look at the main target receptors of caffeine and 
the changing brain of a person with dementia. Subsequently, conclusions on the exploration of 
the relation between caffeine consumption and behavioral symptoms in persons with dementia 
are discussed in detail, including the clinical implications and considerations for further research.
In short, if one assumes that any association will have to be unidirectional and consistently 
linear, one might draw the conclusion that there is no relation between caffeine and behavioral 
symptoms in persons with dementia. However, this thesis provides data to support the argument 
that there is a complex relationship between caffeine and behavioral symptoms in persons with 
dementia, and this relationship differs per person, is dose-dependent, and changes with age and 
the presence of dementia. As caffeine consumption is an easy-to-manage intervention against 
the background of hard-to-manage behavioral symptoms that place a major burden on caregivers 
and reduce the quality of life of the person with dementia, it is advisable to include caffeine 




As the number of patients suffering from dementia is still growing, most of the patients display behavioral symp-
toms at some time during the disease and these behavioral symptoms lower the quality of life and increase the 
burden of caregivers, adequate management of these symptoms is warranted. However, the etiology and man-
agement of behavioral symptoms is complex, resulting in (mis)use of pharmacological interventions: a cure which 
is often worse than the disease. In healthy adults, caffeine is known to influence behavior. Four different studies 
were conducted to see if caffeine is an easy to adjust cause or a pragmatic intervention for behavioral symptoms 
in patients with dementia. The first study found caffeine consumption to be correlated with less apathy, lower ab-
errant motor behavior and getting up at night. The second study found a reduction in caffeine consumption led to 
a decrease in behavioral symptoms (aggression, irritability, general restlessness and aberrant motor behavior) in 
one participant, but no difference in the other participant. A review of literature found few studies on the subject 
and some with severe methodological flaws, therefore no consistent conclusion on the relation between caffeine 
consumption and behavioral symptoms could be drawn. The last study showed behavioral symptoms (like agita-
tion, disinhibition and depression) were most common in persons with low caffeine consumption. Based on these 
studies, we conclude caffeine can influence behavior in persons with dementia, but most likely not in all persons, 
not in all situations and not all of the time; but it can have an influence. In clinical practice it is advisable to consid-






Het woord ‘dementie’ is afgeleid van de Latijnse stam ‘demens’ en betekent letterlijk ‘zonder 
geest’. Het syndroom dementie kan veroorzaakt worden door meer dan 100 ziekten waarbij de 
cognitieve functie sterker verslechtert dan verwacht kan worden op basis van normale veroude-
ring. Alle cognitieve functies zoals aandacht, planning, leren, geheugen, taal, visuele waarneming, 
ruimtelijke vaardigheden of sociale vaardigheden kunnen door dementie worden beïnvloed. Pati-
enten met dementie kunnen ook niet-cognitieve symptomen vertonen, zoals probleemgedrag in 
de vorm van agressie, agitatie, angst, apathie. De etiologie van gedrag bij patiënten met dementie 
is complex. Bijna alle patiënten met dementie zullen op enig moment tijdens de ziekte probleem-
gedrag vertonen dat de kwaliteit van leven van de patiënt verminderen en een zware belasting 
vormen voor de mantelzorgers. Een hogere belasting van de mantelzorger verslechtert vaak de 
relatie tussen de mantelzorger en de patiënt met dementie, wat op zijn beurt de frequentie en 
ernst van het probleemgedrag kan verhogen. Snel en adequaat beheer van gedragssymptomen 
bij patiënten met dementie is noodzakelijk om verdere schade voor de patiënt, overbelasting van 
de mantelzorger, vermijdbare verpleeghuisopnames en vermijdbare maatschappelijke kosten te 
voorkomen.
Volgens de richtlijnen is de eerste stap in het behandelen van probleemgedrag een gedetail-
leerde analyse van het gedrag, inclusief de mogelijk bijdragende fysieke, psychologische, sociale 
en omgevingsfactoren, waarna interventies kunnen worden geformuleerd. Hoewel er enig bewijs 
is dat farmacologische middelen gedragssymptomen bij patiënten met dementie kunnen ver-
minderen, is het klinische effect klein en zijn er grote risico’s op bijwerkingen en zelfs overlijden. 
Psychosociale interventies zijn ook uitgebreid bestudeerd. Het is bewezen dat benaderingen zoals 
gedragsmanagementtechnieken of cognitieve gedragstherapie de symptomen verminderen. Ech-
ter, voor het behandelen van probleemgedrag is er geen gestandaardiseerde oplossing beschik-
baar. Alle interventies gericht op gedrag moeten op het individu worden afgestemd. Maar zelfs 
in deze geïndividualiseerde benadering worden voedingsfactoren niet regelmatig als mogelijke 
oorzaak of ingreep meegenomen.
Cafeïne wordt al enkele eeuwen gebruikt om gedrag te beïnvloeden en de effecten van cafeïne 
op het gedrag bij volwassenen zijn uitgebreid onderzocht. Het is algemeen aanvaard dat matige 
cafeïneconsumptie bij gezonde volwassenen de alertheid, aandacht en cognitieve functie ver-
hoogt. Ook verbetert het de stemming en vermindert vermoeidheid. Een hoge cafeïneconsump-
tie verhoogt angst, kan psychotische of manische symptomen veroorzaken en verslechtert slaap. 
Omdat deze effecten van persoon tot persoon verschillen, passen mensen hun cafeïneconsumptie 
normaal gesproken aan op basis van hun persoonlijke ervaring met (on)gunstige (bijwerkingen) 
effecten. Hoewel het effect van cafeïne op het gedrag van volwassenen algemeen wordt aan-
vaard, is het effect van cafeïne op het gedrag van patiënten met dementie niet goed onderzocht. 
Omdat koffie regelmatig wordt gedronken, overal verkrijgbaar is en de meeste verpleeghuizen 
geen specifieke beperkingen of aanpassingen hebben in het cafeïnegebruik van de bewoners, is 
meer inzicht in de relatie tussen cafeïne en gedrag bij mensen met dementie gewenst.
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Op basis van de bekende stimulerende effecten van cafeïne bij gezonde volwassenen, lijkt 
het logisch om aan te nemen dat cafeïne bij mensen met dementie gedragssymptomen kan 
veroorzaken door algemene rusteloosheid, woede en angst te verhogen en slaapproblemen geeft 
door vermoeidheid te onderdrukken. De slaapproblemen bij mensen met dementie kunnen weer 
leiden tot meer slaperigheid overdag en een omkering van het dag en nacht ritme, wat op zijn 
beurt ook gedragssymptomen kan verergeren (bijv. Prikkelbaarheid).
Maar, het tegenovergestelde kan echter ook worden beredeneerd: cafeïneconsumptie kan 
gedragssymptomen gunstig beïnvloeden door de concentratie te verbeteren en over stimulatie te 
verminderen als gevolg van een verhoogde alertheid. Een ander mogelijk gunstig mechanisme is 
het sociale aspect van cafeïneconsumptie. In het algemeen kunnen sociale activiteiten gedrags-
symptomen bij patiënten met dementie verminderen.
Beide hypothesen werden als even sterk beschouwd, daarom was het doel van dit proefschrift 
om te onderzoeken of er een verband bestaat tussen cafeïneconsumptie en gedragssymptomen 
bij mensen met dementie, en (als er een verband bestaat) om de richting van het effect te bepalen.
Dit proefschrift bestaat uit vier onderzoeken die stapsgewijs zijn uitgevoerd. Als eerste zijn 
twee verschillende onderzoeken gedaan om de hypothesen te verkennen. Als uit deze onder-
zoeken enige validatie van de hypothesen zou komen, dan zou de tweede stap volgen: een 
systematische literatuurstudie en een grote multicenter cohortstudie. hoofdstuk 1 beschrijft de 
observationele pilotstudie die als eerste is uitgevoerd om de mogelijkheid van een verband te 
onderzoeken tussen cafeïne en probleemgedrag bij een groep oudere patiënten met dementie. 
Tijdens deze studie lag de nadruk op slaap, agressie, depressie, angst, apathie, prikkelbaarheid 
en doelloos repetitief gedrag (DRG). Gedurende vier dagen werden deze gedragssymptomen 
gemeten met behulp van de Neuropsychiatric Inventory - Nursing Home edition (NPI-NH) en een 
slaapvragenlijst, samen met een zorgvuldige observatie van het cafeïnegebruik. In deze groep van 
29 ouderen met dementie die op een psychogeriatrische afdeling wonen, werd een negatieve 
correlatie gevonden tussen cafeïneconsumptie en apathie en DRG en een positieve correlatie 
met het ‘s nachts uit bed komen. Er werden geen significante correlaties gevonden tussen cafeïne 
en agressie, depressie, prikkelbaarheid of angst. Deze verkennende studie toonde een verband 
aan tussen cafeïneconsumptie en enkele vormen van probleemgedrag bij een groep mensen met 
matig ernstige dementie.
hoofdstuk 2 beschrijft de tweede verkennende studie. Omdat cafeïne een sterke individuele 
variatie vertoont in effecten op gedrag bij gezonde volwassenen, was de tweede studie bedoeld 
om deze individuele effecten te onderzoeken. Bij twee personen met dementie, een hoog cafe-
inegebruik en ernstig probleemgedrag, is het cafeïnegebruik gereguleerd over een periode van 
vier weken in een geblindeerde cross-over studie. De deelnemers kregen cafeïne houdende of 
cafeïnevrije koffie geserveerd in een vooraf bepaalde volgorde (C-D-D-C). Gedragssymptomen 
werden vervolgens gescoord met behulp van de NPI-NH en de Cohan Mansfield Agitation Inven-
tory (CMAI), met geïndividualiseerde uitkomsten per patiënt. Deelnemer A was een 85-jarige 
vrouw met de ziekte van Alzheimer en deelnemer B was een 91-jarige vrouw met gemengde 
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dementie. Deelnemer A had een afname van haar specifieke gedragssymptomen in de cafeïne-
weken en een kleine toename bij herintroductie van cafeïne. Bij deelnemer B werd echter geen 
verband gevonden tussen cafeïne en het gedrag. Deze tweede studie bevestigde een verband 
tussen cafeïne en probleemgedrag, maar toonde ook de individuele variatie in effecten.
De resultaten van de twee verkennende onderzoeken waren aanleiding tot groter vervolgon-
derzoek. hoofdstuk 3 beschrijft het systematische literatuuronderzoek dat is uitgevoerd volgens 
de Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) richtlijnen. Het 
studieprotocol is geregistreerd bij PROSPERO. Met de onderzoeksvraag “Heeft cafeïne of koffie-
consumptie invloed op neuropsychiatrische symptomen, bijv. agitatie, agressie, apathie, prikkel-
baarheid, bij oudere patiënten met dementie? ” is er gezocht in zes (medische) tijdschriftdatabases 
(Medline (PubMed), Embase, Emcare, Cochrane, PsychInfo en Web of Science) en grijze literatuur 
(GLIN, Greylit, AACN Research & Data center, WHO, OpenGray, HSO en Clinicaltrials.gov). Meer 
dan 4000 artikelen werden door twee recensenten op relevantie gescreend. Na screening op 
geschiktheid bleven slechts zeven artikelen over. De zeven onderzoeken verschilden op vrijwel 
alle facetten: studietype (van casusrapportage tot RCT), publicatiedatum (variërend van 1976 tot 
2018), methodologie (kwalitatief en kwantitatief), de wijze van toediening van cafeïne (dranken 
tot injecties) en het meten van het gedrag. De meeste onderzoeken hadden methodologische 
problemen en ondanks een grondige analyse konden er geen consistente conclusies worden 
getrokken over cafeïneconsumptie en probleemgedrag. Maar, bij elk onderzoek bleek het gedrag 
van sommige deelnemers echter zowel in positieve als in negatieve zin te worden beïnvloed door 
cafeïneconsumptie.
Als vierde is een grote multicenter cohortstudie uitgevoerd met als doel de mogelijke relatie 
tussen cafeïne en probleemgedrag te beoordelen bij een grote groep verpleeghuisbewoners met 
dementie. Dit driejarige onderzoek is ingebed in de opleiding tot specialist ouderengeneeskunde 
en de artsen in opleiding verzamelden gegevens over cafeïneconsumptie, cognitie, gedrag en 
sociale status. De onderzoeksopzet wordt gedetailleerd beschreven in hoofdstuk 4. Voor zover 
wij weten, heeft dit geresulteerd in de grootste bestaande dataset over cognitie, gedrag en cafeï-
neconsumptie onder verpleeghuisbewoners. In hoofdstuk 5 bespreken we de resultaten van een 
subgroep analyse van de mensen met dementie. Iets meer dan 200 personen werden geïnclu-
deerd, van wie 70% gedragssymptomen vertoonde. Mensen die weinig cafeïne consumeerden, 
hadden de meeste kans op gedragssymptomen. Bovendien verschilden sommige gedragssympto-
men tussen personen met milde, matige, matig ernstige en ernstige dementie.
De algemene discussie begint met een verdieping in de belangrijkste receptoren waarop cafeïne 
aangrijpt en het veranderende brein van een persoon met dementie. Daarna worden conclusies 
over de relatie tussen cafeïneconsumptie en gedragssymptomen bij mensen met dementie in 
detail besproken, inclusief de gevolgen voor de praktijken overwegingen voor verder onderzoek. 
Samengevat, als men aanneemt dat een associatie uni directioneel en consistent lineair moet 
zijn, zou men tot de conclusie kunnen komen dat er geen verband bestaat tussen cafeïne en 
gedragssymptomen bij mensen met dementie. Dit proefschrift levert echter het argument dat er 
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een complexe relatie bestaat tussen cafeïne en gedragssymptomen bij mensen met dementie, 
en dat deze relatie verschilt per persoon, dosisafhankelijk is en verandert met de leeftijd en het 
beloop van dementie. Aangezien cafeïneconsumptie een gemakkelijk te beïnvloeden interventie 
is, gedragssymptomen in het algemeen moeilijk te behandelen zijn en een grote belasting vormen 
voor zorgverleners en de kwaliteit van leven van de persoon met dementie verminderen, is het 
raadzaam om cafeïneconsumptie op te nemen in het vocabulaire van de professional als moge-





Isaac Newton schreef aan Robert Hooke in 1675 “if I have seen further it is by standing on the 
shoulders of giants.” Bij mijn promotietraject heb ik van vele schouders gebruik mogen maken. 
Hoewel mijn naam op het proefschrift staat zijn er velen zonder wiens kennis, steun en aan-
moediging dit proefschrift niet geschreven was. Dank aan iedereen op wiens schouders ik heb 
mogen staan, op wiens schouders ik heb mogen leunen en aan hen die me geholpen hebben de 
schouders op te halen.
Dank aan mijn promotieteam. Prof.dr.W.P.Achterberg, eerste-promotor: Beste Wilco, als collega 
SO stimuleerde je de nieuwsgierigheid in een jonge SO. Uit die nieuwsgierigheid is (jaren later) dit 
proefschrift is ontstaan. Dank voor het vertrouwen, de kansen die je hebt gecreëerd, je wijsheid 
en begeleiding. Ik kan me geen prettigere eerste-promotor voorstellen.
Prof.dr.M.E.Numans, promotor: Beste Mattijs, dank voor onze gesprekken en je perspectief, zowel 
op dit onderzoek als op de rest van mijn werkzaamheden.
Dr.N.Rius-Ottenheim, co-promotor: Beste Nathaly, bij jou kon ik terecht voor antwoorden op 
praktische vragen, voor nuanceringen en overwegingen. Dank voor waardevolle feedback, ik keek 
er iedere keer weer naar uit.
Zonder de aan de onderzoeken deelnemende mensen met dementie en hun vertegenwoordigers, 
de verzorgenden van Zorgspectrum en de aios specialisme ouderengeneeskunde in Leiden, waren 
deze onderzoeken niet mogelijk geweest. Dank voor jullie betrokkenheid en inzet. Ik hoop dat de 
conclusies bijdragen aan een betere kwaliteit van leven en goede koffie.
Tijdens het promotietraject heb ik veel vragen gesteld, zowel inhoudelijk als procedureel. Dank 
aan de collega docenten en onderzoekers, Joran Jongerling, Linda Breeman en anderen voor het 
beantwoorden van mijn vragen en het stellen van nog meer vragen. En dank aan José Tielerman-
Shamier, die mogelijkheden zag in agenda’s waar alleen maar overlap zichtbaar was.
Maxim Veen, Joost Leopold, Wilco Admiraal en andere barista’s hebben me geleerd dat er zoveel 
meer in koffie zit en er zoveel (smaak)nuance mogelijk is, als je weet welke factoren je kan beïnv-
loeden. Dank voor de verdieping in iets alledaags.
Onder het genot van vele goede koppen koffie hebben Maaike de Jong, Stefan van Osch, Bastiaan 
Smit, Jantine van den Bosch, Erik van Tulder en Linda Breeman geluisterd, gerelativeerd en genu-
anceerd. Jullie schouders heb ik nodig gehad en gewaardeerd.
Dank aan mijn ouders en grootouders, jullie zijn reuzen.
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selection of relevant oral and poster presentations
2019  Presentation on behavioral symptoms in persons with dementia and the law 
‘Als het niet anders kan’, at V&VN POH/PVK congress
2017-2018  Workshop “de verschillende gezichten van dementie”, at V&VN congress
2017  Presentation “Elderly care specialist training – does it refer to dignity?” at 
LUMC international congress “Dignity in old age”
2016  Presentation “Probleemgedrag – geen probleem voor de praktijkverpleegkun-
dige” V&VN congress
2016  Workshop (with Corinne de Ruiter, Verenso) “De specialist ouderenge-
neeskunde van de toekomst” at Verenso congress Dementia & Domotica
2015  Presentation “Hoe leiden we de SO van de toekomst op?” at My-Doc congress 
Artsen in control
2014  Presentation (with F.J.Bruijel, psychologist) “Mevrouw hangt in de gordijnen - 
rollen en keuzes van de praktijkverpleegkundige bij probleemgedrag” at V&VN 
congress
2014  Presentation “Samenwerking tussen specialisten ouderengeneeskunde en 
huisartsen” at Zorgspectrum congress ‘een dementievriendelijke gemeente’
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2014  Presentation “Kopje koffie mevrouw Jansen – de relatie tussen cafeïne en ge-
drag bij mensen met dementie” at Boerhaave Vorderingen in het specialisme 
ouderengeneeskunde
2010  Presentation “cafeïne en probleemgedrag bij dementie” at Verenso Congress
2010  Posterpresentation at IPA congress “The effect of caffeine on behavioral prob-
lems in elderly patients with dementia”
2008  Panelmember at congress ‘Bewegingsvrijheid voor mensen met dementie’ 
vereniging voor psychogeriatrie in samenwerking met stichting IDé
2006  Posterpresentation “Antipsychotic drug use and hypothermia” at the research 
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